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DEVELOPMENT OF RATIONAL COMBINATION THERAPY WITH  
PARP INHIBITORS AND KINASE INHIBITORS IN TNBC 
 
Wen-Hsuan Yu, B.S. 
Advisory Professor: Mien-Chie Hung, Ph.D. 
Poly (ADP-ribose) polymerase inhibitors (PARPi) emerge as potential targeting 
drugs for BRCA-deficient cancers including triple negative breast cancer (TNBC). 
However, it has been reported that a subgroup of patients even with BRCA mutation fails 
to respond to PARPi in multiple clinical trials. In this study, we identified c-Met, a 
tyrosine kinase, phosphorylates PARP1 at Y907 and that the phosphorylation increases 
PARP1 activity, thereby rendering cancer cells resistant to PARPi. The combination of c-
Met inhibitors (METi) and PARPi has a synergistic effect for c-Met overexpressed 
TNBC in vitro and in vivo. In addition to c-Met, through functional analysis, we found 
casein kinase 2 (CK2) is another potential PARP1 regulator. The combination of a CK2 
inhibitor (CK2i) and PARPi synergistically attenuates DNA damage repair, cell cycle, 
cell proliferation and xenograft tumor growth. Similar to the c-Met-PARP1 axis, CK2 
interacts with PARP1 in the nucleus. Moreover, CK2 can phosphorylate PARP1 in vitro, 
implicating that similar to c-Met, CK2 regulates PARP1 activity through direct 
phosphorylation. Together, phosphorylation of PARP1 may be used as biomarkers to 
guide the combinational treatment of PARPi and corresponding kinase inhibitors. Our 
study not only has revealed a new mechanism of PARPi resistance but also provided a 
marker-guided combination therapeutic strategy to stratify TNBC patients who do not 
respond to PARPi.  
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INTRODUCTION 
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1.1 Overview of Breast Cancer 
Breast cancer is the most common cancer diagnosed among US women, 
accounting for approximately one in three cancer populations (1). In the U.S., the rates of 
breast cancer death are higher than those for any other cancer except for lung cancer. 
According to the statistics from National Cancer Institute (NCI), there were 230,000 
female breast cancer cases and caused about 40,000 deaths in 2015.  
Breast cancer can be divided into different types by the tissue histopathology, 
including ductal carcinoma, lobular carcinoma and inflammatory breast cancer (2). 
Among them, ductal carcinoma is the most common type of breast cancer, making up 
nearly 70-80% of all breast cancer population. Staging of breast cancer by TNM system 
has important implications for cancer prognosis and therapy (3). The current therapies for 
breast cancer included surgery, radiotherapy, chemotherapy, hormone therapy and target 
therapy (4). Surgery is the most recommended therapy for patients with early stages (I or 
II) breast cancer (5). In patients with unresectable tumors (stage III or IV), chemotherapy 
or combination with radiotherapy, hormonal therapy, or target therapy is considered to be 
the standard treatment (6, 7). Until now, many effective chemotherapy drugs have been 
discovered to against breast cancer (8). The most common chemotherapy drugs include 
paclitaxel (Taxol®), docetaxel (Taxotere®), doxorubicin (Adriamycin®), epirubicin 
(Ellence®), methotrexate (Trexall®), 5-fluorouracil (5-FU; Adrucil®), cyclophosphamide 
(Cytoxan®) and carboplatin (Paraplatin®). Combination chemotherapy treatment is 
usually used to treat breast cancer. For example, CMF (cyclophosphamide, methotrexate 
and 5-FU) is a common used regimen for breast cancer (9).  
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Breast cancer can be divided into three subtypes by the protein expressions of 
estrogen receptor (ER), progesterone receptor (PR) and ERBB2 (HER2/neu), including 
luminal types, HER2-positive types and basal-like types (10). Luminal types breast 
cancer are ER-positive tumors, and the gene expression patterns of these tumors are 
similar to normal tissues that line the breast ducts and glands. Luminal types breast 
cancer can be further classified into two subtypes: luminal A and luminal B. Luminal A 
breast cancer tends to grow slowly, which have better prognosis. Luminal B breast cancer 
typically grows faster than luminal A. HER2-positive breast cancer is a breast cancer that 
highly expresses human epidermal growth factor receptor 2 (HER2), which can promote 
tumor growth, accounting for approximately 1 of 5 breast cancer cases. HER2-positive 
breast cancers tend to be more aggressive than luminal types breast cancer. Basal-
like breast cancer (BLBC) makes up about 15-20% of breast cancers. Tumors that are 
negative for ER, PR, and HER2 expression are referred to as triple-negative breast 
cancers (TNBCs) (11).  
 
1.2 Background of Triple-Negative Breast Cancer (TNBC) 
As mentioned earlier, TNBC is a subtype of breast cancer that phenotypically lack 
of ER, PR and HER2 expressions (11). This subtype accounts for approximately 15-20% 
among all breast cancer patients. Majority of TNBC are high grade and invasive, 
resulting in distant metastases and poor survival rates. Women with TNBC do not 
respond to hormonal therapies or HER2-targeted agents because of the lack of ER, PR, 
and HER2 amplification (12). Recent studies using clinical samples indicate that TNBC 
and BLBC are 80% similar (13). More recently, TNBCs have been further classified into 
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six subtypes according to gene expression profiles (14), indicating that TNBCs are highly 
heterogeneous. Therefore, the development of the effective treatment strategies for 
TNBC is urgently needed. 
BRCA1 and BRCA2 are the enzymes involved in homologous recombination 
(HR) DNA repair pathway. BRCA1 was first found to be involved in breast and ovarian 
cancer in 1990’s (15). Later, BRCA2 was identified to have similar functions with 
BRCA1 (16). Further studies showed that BRCA1 mutations are correlated with early-
onset of breast and ovarian cancers (17, 18). More detail investigation further revealed 
that both BRCA1 and BRCA2 are involved in the progression of breast cancer through 
functional loss of mutations, which is deficient in HR repair of damaged DNA (19-21). 
Currently, BRCA mutations are considered as key bio-markers to predict the hereditary 
breast or ovarian cancer. A recent study showed that more than 30% TNBC patients have 
BRCA mutations and BRCA1-mutation patients have same histological characteristics 
and clinical outcome with TNBC patients (22).  
 
1.3 Overview of DNA Damage and Repair  
DNA damage is an alteration in the chemical structure of DNA, which includes 
base and sugar modifications, single-strand breaks (SSBs), double-strand breaks (DSBs) 
and DNA-protein cross-links (23). DSBs can lead to genome rearrangements that are 
particularly hazardous to the cell. DNA damage could occur from various endogenous 
and exogenous resources. For example, oxidative DNA damage is frequently occurred by 
reactive oxygen species (ROS) in many human tissues, especially in tumors (24, 25). 
ROS could be produced from endogenous metabolic process such as oxidation, alkylation 
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and hydrolysis of bases (26-28). Endogenous DNA damage occurs more often than 
exogenous damage that is caused by external agents such as ultraviolet (UV) light, 
radiation, several plant toxins, mutagenic chemicals and virus infection (29, 30). DNA 
damages occur naturally thousands of times every day during each cell cycle in humans, 
and that damages must be repaired by different DNA repair mechanisms to remove 
different types of DNA damages and restore the DNA duplex (31). To counteract DNA 
damage, cells have developed specialized DNA repair systems, which can be subdivided 
into several distinct mechanisms based on the types of DNA damage. These processes 
include base excision repair (BER), mismatch repair (MMR), nucleotide excision repair, 
and DSBs repair, which comprise both non-homologous end-joining (NHEJ) and 
homologous recombination (HR) (32) .  
DNA repair systems are consist of multiple repair enzymes, and allow both RNA 
and DNA polymerases to read accurately and duplicate the information in the genome 
(33). These repair mechanisms are regulated by various DNA damage response kinases, 
which are activated at DNA lesions. These kinases can phosphorylate repair proteins to 
modify their activities, or initiate a complex series of changes in the local chromatin 
structure near the damage sites to improve the efficiency of DNA repair (32). 
 
1.4 Poly-ADP-Ribose Polymer (PARP) in DNA Repair 
Poly (ADP-ribose) polymerase (PARP) is an enzyme that transfers poly (ADP-
ribose) (PAR) chain to various acceptor proteins such as histone, DNA repair proteins 
and PARP itself. This process plays a critical role in DNA repair (34, 35). PARP1 is 
responsible for approximately 90% of the ADP-ribosyl transferase activity [poly (ADP-
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ribose)ylation (PARylation)] in cells (36). When cells are exposed to alkylating agents, 
ionizing radiation or free radicals, PARP detects and rapidly binds to DNA strand breaks 
and catalyzes PARylation mainly of itself using NAD+ as substrate (34). Upon the 
formation of long, branched polymers, PARP is released from DNA, and then the 
polymers are degraded by the PARG enzyme, allowing the access of the DNA repair 
machinery to the lesion sites (34).  
PARP1 has a key role in BER, SSBs, and DSBs repair. In addition, PARP1 has 
been implicated in HR at stalled or collapsed replication forks, as well as regulating 
nonhomologous end-joining (NHEJ) repair (35). In response to DNA damage, PARP1 
enzymatic function is activate and correlated with the extent of the damage (37). When 
DNA breaks are repairable, PARP1 activates the repair and cell cycle machineries; while 
in response to catastrophic damage, PARP1 induces cell death. For example, PARP1 
binds to a DNA SSBs and catalyses the formation of PAR polymers on itself and other 
acceptor proteins. PAR formation is suggested to be important to protect DNA breaks, 
alter chromatin structure and to attract DNA repair proteins to the site of damage (38). 
Therefore, inhibition of PARP1 results in inactivation of the DNA repair machinery and 
causes more SSBs, which may subsequently induce the formation of DSBs. 
 
1.5 Mechanism of Action of PARP Inhibitors (PARPi)  
The structure of PARPi includes a nicotinamide moiety that competes with 
NAD+. They are highly efficacious PARP catalytic inhibitors with IC50 values reaching 
the low nanomolar range (39). PARPi that compete with NAD+ at the enzyme's activity 
site can be used in BRCA-deficient cells as single treatment acting through the principle 
of synthetic lethality exploiting these deficient DNA DSBs repair in these cells (40, 41). 
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In addition to catalytic inhibition, recent studies suggested that selective PARPi induce 
cytotoxicity by trapping PARP-DNA complexes (42, 43). PARP can’t dissociate from the 
DNA and prevent DNA replication and transcription, leading to cell death.  
 
1.6 Current Development of PARPi in Clinical Trial 
Several PARPi including olaparib (AZD-2281), veliparib (ABT-888), rucaparib 
(AG-014699; CO-338), niraparib (MK4827), and talazoparib (BMN673) are currently 
using in clinical trials as single agent or combined with chemo-drugs. Among them, 
olaparib is the most-investigated one in cancer treatment. Olaparib (Lynparza®) is the 
first PARP inhibitor, which was approved as monotherapy to treat ovarian, fallopian tube, 
and primary peritoneal cancer in women carrying BRCA1 or BRCA2 mutations by U.S. 
FDA on December 19, 2014. Recently, olaparib has been evaluated as adjuvant therapy 
in patients with TNBC. A phase I trial that recruited total 60 TNBC patients, of whom 22 
were carriers with a germline mutation of BRCA1 or BRCA2. Eight patients received 
400 mg of olaparib twice daily and only one of them had reversible dose-limiting toxicity 
This result suggested the safety dose of olaparib (44).  
More than 127 US National Cancer Institute (NCI)-registered clinical trials have 
been launched to evaluate a range of compounds in combination with PARPi (45). In 
addition to BRCA1/2 mutations, DNA repair gene deficiency, mutation of transcription 
regulation gene and cell cycle control dysregulation are proposed as biomarkers of cancer 
sensitivity to PARPi alone or in combination with cytotoxic drugs in clinical trials (46, 
47). For example, in a phase I study in patients with refractory multiple myeloma (MM), 
the combination of PARPi, veliparib, and proteasome inhibitor, bortezomib, seemed to be 
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well tolerated, with strong evidence of considerable antitumor activity (ClinicalTrials.gov 
Identifier: NCT01495351). In another phase I study, olaparib has been combined with 
alkylating agent dacarbazine for treating patients with advanced solid tumors, and the 
results showed to be well tolerated (48). In a phase III study, the combination of 
gemcitabine and carboplatin with PARPi iniparib was associated with potential benefits 
in overall response rate (ORR) in TNBC patients treated with this regimen (49). It is 
worthy to note that not all patients with BRCA mutation response to PARPi in clinical 
trials, suggesting other mechanisms that can compensate for BRCA deficiency. 
 
1.7 Resistance to PARP Inhibitors in Cancer Therapy 
Growing numbers of studies are being conducted to explain the molecular 
mechanisms underlying intrinsic and acquired resistance to PARPi. Such mechanisms, 
for example, include secondary BRCA mutations that regain BRCA function, and 
enhance P-glycoprotein-mediated drug efflux (50). Inhibition of NHEJ core proteins, 
such as loss of 53BP1 protein, has been shown to contribute to the development of 
PARPi resistance by restoring HR activity (51), and deficiency in other crucial NHEJ 
players, Ku70/80 and DNA-PK, contributes to PARPi resistance in BRCA1-deficient 
cells (52). Recently, HOXA9 has been shown to contribute to PARPi resistance of MML 
though upregulation of HR genes (53). These important studies provide certain 
mechanisms to explain resistance to PARPi. However, to make PARPi effective, it is still 
a critical challenge to identify mechanisms that could provide biomarkers to stratify 
patients who will respond to PARPi treatment as well as effective rational combinational 
therapy for those who will not respond to PARPi.  
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1.8 Post-Translational Modifications (PTMs) and Regulation of PARP1  
Post-translational modifications (PTMs) are enzymatic modification of proteins to 
indicate the protein functions and to regulate the signaling networks (54). The PTMs 
occur on the amino acid side chains or at the C- or N-terminal of proteins including 
glycosylation, phosphorylation, acetylation, methylation, ubiquitination, 
nitrosylation, lipidation and proteolysis. These modifications affect almost every 
aspect of cell function (54).  
The PTMs of PARP1 have been discovered in the past few years. Most of the 
studies focused on how PARP1 is covalently modified and how PTMs could regulate the 
activity and function of PARP1. Those modifications include ADP-ribosylation, 
phosphorylation, acetylation, methylation, ubiquitylation and SUMOylation (55). Take 
phosphorylation as an example, a broad proteomic screen has identified a variety of 
phosphorylation sites on PARP1 (56). These phosphorylation sites have been investigated 
in more details in functional studies. PARP1 is phosphorylated at Ser 372 and Thr 373 by 
ERK1/2, and these modifications are required for PARP1 activation after DNA damage 
(57). PARP1 can also be phosphorylated by JNK1 at undetermined sites, which sustained 
PARP1 activation during H2O2-induced non-apoptotic cell death (58). However, 
phosphorylation of PARP1 does not always promote an increase in PARP1 activity (59, 
60). It has been shown that protein kinase C (PKC)-mediated PARP1 phosphorylation 
results in decreased PARP1 DNA-binding and catalytic activity. Therefore, more studies 
are needed to fully understand the role of other kinases on PARP1 (59).  
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1.9 Overview of c-Met Kinase 
Receptor tyrosine kinases (RTKs) regulate many cellular processes in mammalian 
development, cell function and tissue homeostasis. c-Met (MET or hepatocyte growth 
factor receptor (HGFR)) is one of RTKs that has been implicated to play important 
biological roles in mammalian cells (61). c-Met is formed by proteolytic processing of a 
common precursor in the post-Golgi compartment into a single-pass, disulphide-linked 
α/β heterodimer (62). The functional structures and domains of c-Met includes the sema 
domain, PSI (found in plexins, semaphorins and integrins) domain, four IPT 
(immunoglobulin, plexin, transcription) repeats, transmembrane (TM) domain, 
juxtamembrane (JM) domain and tyrosine kinase (TK) domain (62).  
The ligand for c-Met is hepatocyte growth Factor (HGF), which also known as 
scatter factor (63). HGF can serve as a pleiotropic factor and cytokine that promotes cell 
proliferation, survival, motility, scattering, differentiation and morphogenesis (64). HGF 
is highly related to members of the plasminogen serine protease family and secreted by 
fibroblasts and smooth muscle cells (65). The high-affinity c-Met binding domain of 
HGF is in the N-terminal portion of α chain, while the β chain is important for interaction 
with c-Met (66). Binding of HGF leads to c-Met receptor dimerization and 
autophosphorylation of multiple tyrosine residues. For example, HGF induces 
phosphorylation of Y1230, Y1234 and Y1235 located within the catalytic loop of the 
tyrosine kinase domain, thus activate the intrinsic kinase activity of c-Met (67). On the 
other hand, binding of HGF may also phosphorylate Y1003 in the JM domain and recruit 
c-Cbl E3 ubiquitin ligase to monoubiquitinate c-Met, leading to the internalization and 
degradation by proteasome (68). Therefore, the tyrosine phosphorylation sites play 
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important roles in the regulation and activation of c-Met signaling. 
However, dysregulation of c-Met has been found in various of human cancers, such 
as lung cancer, mesothelioma, colorectal cancer, head and neck cancer, esophageal 
cancer, gastric cancer, pancreatic cancer, sarcomas, thyroid cancer, ovarian cancer, breast 
cancer, cervical cancer, brain tumors, and especially hereditary papillary renal cell 
carcinomas (61, 66, 69). Studies have shown that c-Met can be overexpressed, mutated or 
amplified in cancer cells and leads to tumor progression, epithelial mesenchymal 
transition (EMT) and tumor metastasis (70). Therefore, targeting c-Met is an attractive 
strategy for cancer therapy.  
 
1.10 Current Development of c-Met Inhibitors 
 Many c-Met kinase inhibitors are currently used in clinical trials such as tivantinib, 
savolitinib, crizotinib, foretinib, cabozantinib and etc. Among them, crizotinib and 
cabozantinib were the first two small molecule inhibitors to be approved by U.S. FDA 
(71). Crizotinib is known to target multiple kinases including anaplastic lymphoma 
kinase (ALK), c-Met, ROS1 and RON receptors and it is approved to use in ALK-
rearranged advance non-small cell lung cancer (NSCLC) (72, 73). There are 100 US 
NCI-registered clinical trials have been launched to evaluate the therapeutic efficacy of 
crizotinib as a single drug or in combination with other compounds in various types of 
cancer. Currently, one phase I study of the combination of crizotinib and sunitinib is 
designed to test the safety and tolerability with metastatic breast cancer 
(ClinicalTrials.gov Identifier: NCT02074878). In addition, increasing evidence showed 
that c-Met is involved in resistance to many targeted therapies including EGFR inhibitors, 
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VEGFR inhibitors, anti-HER2 and BRAF inhibitors (74-78). For example, it has been 
reported that c-Met signaling can compensate for EGFR inhibition by tyrosine kinase 
inhibitor, erlotinib, in lung cancer (74). The combined inhibition of c-Met and EGFR can 
overcome the resistance. Several combination treatments of c-Met inhibitors and EGFR 
inhibitors have been tested in clinical trials. Moreover, the combination of VEGF 
inhibitor  (axtinib) and c-Met inhibitor (crizotinib) increased the antitumor efficacy in 
RCC mice model (79). These data suggest that c-Met might be a potential target to inhibit 
both molecular driver and resistance regulator. 
 
1.11 Overview of Casein Kinase 2 (CK2) 
Casein Kinase 2 (CK2) is a constitutively active serine/threonine kinase and is 
highly conserved in eukaryotic cells (80, 81). CK2 is a tetramer of two alpha (α and α’) 
subunits and two beta (β) subunits. Depending on different cell types, the catalytic 
subunits are linked via the regulatory subunits to form either the heterotetramer or 
homotetramer such as α2β2, αα’β2, or α’2β2 (82). However, the subunits can also exist 
and function individually in cells. The alpha subunits contain the catalytic kinase domain 
of CK2. The β subunits mediate the autophosphorylation of CK2 protein, and that is 
important to assemble and stable the holoenzyme. Furthermore, β subunits regulate the 
recruitment of distinct substrates, thus regulating the selectivity of substrate by enzyme 
(83). CK2 has many substrates, therefore it can regulates multiple cell functions including 
cell proliferation, cell differentiation, cell cycle, DNA repair, and regulation of circadian 
rhythm (81, 84, 85)  
CK2 has been found to be overexpressed in many cancers such as ovarian and 
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breast cancer (86). Studies have shown that increased expression and activity of CK2 are 
associated with human cancers, while overexpression of CK2 in transgenic mouse models 
result in tumor growth (87, 88). It has been reported that CK2 phosphorylated and 
regulated the activity and stability of various tumor suppressor proteins such as PML, 
p53, and PTEN, as well as oncogenes and transcriptional activators such as c-Myc, c-
Myb, c-Jun, NFkB, and β-catenin (86). Recent studies have demonstrated that CK2 could 
act as suppressor of apoptosis through phosphorylation of pro-apoptotic proteins, which 
protected them from caspase-mediated cleavage (89). Studies also showed that inhibition 
of CK2 sensitized tumor cells to TNF-related apoptosis-inducing ligand (TRAIL) 
receptor-mediated apoptosis, ionizing radiation and chemotherapeutic agents (90). In 
addition, several recent studies reported that CK2 could also regulate epithelial-to-
mesenchymal transition (EMT), which is an early step in cancer invasion and metastasis 
(91).  
 
1.12 CK2 in Cancer 
It has been reported that the activity of CK2 and protein expression levels can 
influence the acquisition and maintenance of the emerging cancer hallmarks in several 
different ways that originally described by Hanahan and Weinberg (92). CK2 can 
regulate the expression of various proteins essential for proliferation, evading growth 
suppressors, avoiding immune destruction, enabling replicative immortality, tumor-
promoting inflammation, invasion, metastasis, angiogenesis, regulating genome 
instability, resisting cell death and deregulating cellular energetics (93). These are all 
highly relevant to cancer progression. 
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Take breast cancer as an example, it has been found that overexpression of CK2α 
in the mammary gland of transgenic mice could promote hyperplasia and neoplasia, 
suggesting CK2 contributed to the development of breast cancer (94). In addition, the 
upregulation of CK2 activity was observed during the development of 7, 12-
Dimethylbenz[a]anthracene (DMBA)-induced mammary tumors in vivo (88). In mouse 
models, CK2 cooperatively promotes tumor formation and progression with 
overexpression of oncogenes such as c-myc or with loss of tumor suppressor genes such 
as p53 (95, 96). Moreover, CK2 activity is higher in human breast cancer tissues 
compared to normal ones, indicating the pathologic relationship between CK2 and breast 
cancer tumorigenesis (88). Clinical breast tumor samples displayed positive correlation 
between CK2 and several EMT markers such as snail (91). Furthermore, at the mRNA 
level, both CK2α and CK2β are elevated and associated with a poor survival prognosis 
and metastasis in patients with all breast cancer subtypes (97). These results indicate that 
CK2 may play an important role in cellular transformation and tumorigenesis. Thus, 
targeting CK2 may serve as an effective strategy for cancer therapy. Therefore, CK2 
inhibitors have been suggested as promising drugs for cancer treatment. CX-4945 is a 
CK2 inhibitor, which is currently under some clinical trials in patients with various 
advanced tumors (45). 
 
1.13 The Role of CK2 in DNA Damage and Repair 
CK2 has recently gained interest in the field of cancer research as both a regulator 
of survival pathways and a modulator of the DNA-repair machinery. CK2 was shown to 
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regulate the function of several enzymes of the DNA-repair and DNA-damage sensing 
machinery, such as XRCC1 and XRCC4, Rad9 and DNA-PK. 
The X-ray repair cross-complementing group 1 (XRCC1) is a member of a family 
of XRCC proteins (98). XRCC1 can directly bind to DNA SSBs, which play important 
roles in DNA repair. XRCC1 interacts with PARP and DNA ligase to participate in BER 
and HR (99). CK2 has been shown to phosphorylate XRCC1 and thereby enable the 
assembly and activity of DNA SSBs repair at sites of chromosome breakage (100). CK2 
can also phosphorylate XRCC4, which is known to be one of the proteins involved in 
non-homologous end joining (NHEJ) pathway to repair DNA DSBs (101). Furthermore, 
phosphorylation of XRCC4 is necessary for its interaction with PNK. This interaction is 
important for DNA DSBs repair. Together, these results demonstrate that CK2 regulates 
not only SSBs repair but also DSBs repair. 
 
1.14 Current Development of CK2 Inhibitors 
CX-4945 is a selective CK2 ATP-competitive inhibitor, initially discovered by 
Cylene Pharmaceuticals Incorporation (102). CX-4945 can cause cell cytotoxicity and 
apoptosis and some clinical trials are currently performed in different cancer types to 
evaluate the effectiveness of the drug. For example, in hematological tumors, CX-4945 
shows anti-proliferation effects by suppressing CK2 expression and inhibiting activation 
of PI3K/Akt/mTOR signaling pathway, which is mediated by CK2 (103). Moreover, 
combined CX-4945 with other inhibitors such as PI3K inhibitors had synergistic effects 
(104). Therefore, CX-4945 is a potential therapeutic target for combinational treatment in 
human cancers. 
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Currently, CX-4945 is investigated in Phase I and II clinical trials in multiple 
human cancers. For example, the phase I study of oral CX-4945 is evaluated the safety, 
tolerability and highest safe dose levels of this CK2 inhibitor in patients with advanced 
solid tumor cancers, Castleman's Disease or multiple myeloma (ClinicalTrials.gov 
Identifier: NCT00891280). Another phase 1 study is designed to test the dose, safety, 
pharmacokinetics, and Pharmacodynamics of CX-4945 in patients with relapsed or 
refractory multiple myeloma (ClinicalTrials.gov Identifier: NCT01199718). The 
subsequent Phase I/II trial is a randomized study of antitumor activity in 
cholangiocarcinoma patients, comparing the standard-of-care protocol of gemcitabine 
plus cisplatin against treatment with CX-4945 in combination with gemcitabine plus 
cisplatin at the combination maximum tolerated dose (MTD) (ClinicalTrials.gov 
Identifier: NCT02128282).  
 
1.15 Rationale and Hypothesis  
TNBC is an aggressive subtype of breast cancer that initially responds to 
chemotherapy, but a majority of patients eventually develop resistance. Currently, PARPi 
are widely evaluated in clinical trials because TNBC has similar properties with BRCA-
mutated cancers. However, some BRCA-mutated tumors are reported to be resistant to 
PARPi, suggesting mechanisms that can compensate for BRCA deficiency. Thus, it is 
critical to develop strategies to increase the effectiveness of PARPi treatment and to 
identify biomarkers with which to stratify TNBC patients for better therapy. PTM is 
important to the function of PARP1 and phosphorylation signaling is relatively easy to be 
targeted. Therefore, we hypothesized that PARP1 protein is regulated by its 
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phosphorylation. Thus, the phosphorylation status of PARP1 and the expression of the 
kinases that phosphorylate PARP1 may serve as appropriate biomarkers for 
combinational treatments. In this study, we utilized antibody array, database analysis and 
in vitro functional characterization to identify potential regulators for PARPi resistance. 
The long-term goal of this study is to develop the marker-guided combinational treatment 
of PARPi for TNBC.    
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CHAPTER 2 
MATERIALS AND METHODS 
Part of this chapter is taken verbatim by permission from the Nature publishing group: Yi 
Du, Hirohito Yamaguchi, Yongkun Wei, Jennifer L Hsu, Hung-Ling Wang, Yi-Hsin Hsu, 
Wan-Chi Lin, Wen-Hsuan Yu, Leonard, Gilbert R Lee IV, Mei-Kuang Chen, Katsuya 
Nakai, Ming-Chuan Hsu, Chun-Te Chen, Ye Sun, Yun Wu, Wei-Chao Chang, Wen-
Chien Huang, Chien-Liang Liu, Yuan-Ching Chang, Chung-Hsuan Chen, Morag Park, 
Philip Jones, Gabriel N Hortobagyi & Mien-Chie Hung. Blocking c-Met mediated 
PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nature 
Medicine, 2016, 22(2), 194-201(105) 
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2.1 Cell Culture 
All cells were obtained from American Type Culture Collection (ATCC).  Cells 
were cultured in Dulbecco’s Modified Eagle’s Medium cells (DMEM) or in RPMI 1640 
and maintained at 37 °C in 5% CO2. All mediums were supplemented with 10% FBS.  
 
2.2 Transfection, Plasmids and RNAi  
Plasmid DNA transfection was conducted by Lipofectamin 2000 (Thermo Fisher 
Scientific) according to the manufacture’s instruction. The plasmid of Myc-CK2β 
(Addgene plasmid, #27091) was obtained from Addgene. The plasmids that express HA-
PARP1, V5-PARP1 and Flag-c-Met were constructed on pCDH-CMV-MCS-EF1-
Puromycin vector (#CD510B-1; System Biosciences). For stable knockdown of c-Met or 
PARP1 and c-Met or PARP1 overexpression studies, breast cancer cells were transfected 
with pGIPZ shRNA (control) vector (Thermo Fisher Scientific, Rockford, IL) or 
pLKOshRNA vector Sigma-Aldrich (St. Louis, MO) and pCDH-neo vector (System 
Biosciences, Mountain View, CA). siRNA transfection was conducted with use of 
Amexa Nucleofactor II (Lonza Group Ltd., Basel, Switzerland) according to the 
manufacture’s instruction. Sequences of shRNA and siRNA are listed in Table 2.1. 
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Table 2.1 Information about shRNA and RNAi 
Name Purpose Sequence or other information 
Met shRNA CCATCCAGAATGTCATTCT; 
GCATTAAAGCAGCGTATC; 
GCATTAAAGCAGCGTATC*; 
TGTGTTGTATGGTCAATAA; 
CCTTCAGAAGGTTGCTGAGTA; 
PARP1 shRNA TGGAAAGATGTTAAGCATTTA* 
CK2α siRNA SASI_Hs01_00110178; Clone ID (From Sigma-Aldrich) 
CK2α’ siRNA SASI_Hs01_00087712; Clone ID (From Sigma-Aldrich) 
*Targeting the 3′-UTR. 
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2.3 Chemicals and Inhibitors 
Hydrogen peroxide (#216763), and sodium arsenite solution (#35000) were 
obtained from Sigma-Aldrich (St. Louis, MO). PARP inhibitors ABT-888 (Veliparib, 
#CT-A888) and AG-014699 (Rucaparib, #CT-AG01) were from ChemieTek 
(Indianapolis, IN); AZD-2281 (Olaparib, #S1060) and BMN-673 (Talazoparib, #S7048) 
were from Selleck Chemicals (Houston, TX). c-Met kinase inhibitors crizotinib (#C-
7900) and foretinib (#F-4185) were from LC Laboratories (Woburn, MA). CK2 kinase 
inhibitor CX-4945 (Silmitasertib, #200843) was from MedKoo (Chaple Hill, NC). CDK2 
inhibitor SNS-032 (BMS-387032, #S1145) and PKC inhibitor sotrastaurin (#S2791) were 
from Selleck Chemicals (Houston, TX). 
 
2.4 Immunoprecipitation, Immunoblotting and Antibodies 
For immunoprecipitation assay, cell lysates were obtained with modified RIPA 
buffer (25mM Tris-HCl pH7.6, 150mM NaCl, 1% NP40, 1mM DTT). Protein complexes 
were pulled down from antibody/lysate (1 mg, overnight incubation at 4 °C) by protein 
A/G beads. Protein complexes were then washed 5 times and subsequently released by 
SDS-loading buffer. The immunoblot assay was conducted following standard 
procedures. All primary antibodies were used according to the manufactory datasheet. 
The mouse phospho-Y907-PARP1 antibody was generated against a phosphorylated 
synthetic peptide (ADMVSKSAN-Yp-CHTSQGD) at China Medical University, Center 
of Molecular Medicine. Detailed information about all of the antibodies is listed in the 
Table 2.2. 
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Table 2.2 Antibodies List Used in this Study 
Protein Company Purpose Catalog number 
Tubulin Sigma-Aldrich WB T5168 
Flag Sigma-Aldrich WB, IP F3165 
Actin Sigma-Aldrich WB A2066 
γ-H2AX EMD Millipore WB, IF 05-636 
GST Santa Cruz WB sc-53909 
HA Santa Cruz WB, IP sc-805 
V5 ThermoFisher WB, IP MA5-15253 
Myc Roche WB, IP 11667203001 
c-Met Cell Signaling WB, IP, IF 8198 
Phosphor-Met 
(Tyr1234/1235) 
Cell Signaling WB 3077 
CK2α Cell Signaling WB, IP 2656 
PARP1 Cell Signaling WB, IP, IF 9532 
PARP1 BD Pharmingen IF 556362 
PARP1 Santa Cruz WB sc-7150 
CK2α prime Abcam WB Ab10474 
CK2β Abcam WB Ab133576 
CK2β Bethyl Lab IP, IF A301-984A 
PAR Trevigen WB 4335 
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2.5 ROS Detection 
The assay was performed as previously described (105). Cells were seeded in the 
12- or 96- well plates. After overnight growth, cells were incubated with 10 µM 2′,7′-
dichlorofluorescindiacetate (DCFDA) in PBS for 30mins. Cells were washed and the 
media replaced with PBS. 2′,7′-dichlorofluorescein (DCF) was measured under a Zeiss 
microscope with spectra of 495 nm excitation/529 nm emission. Fluorescence intensity 
was measured by AxioVision software. The mean ± s.d. of DCF intensity from five 
images in each cell line was calculated.  
2.6 Hierarchical Clustering and Display  
The assay was performed as previously described (105). Clustering of any set of 
PARP1-associated kinase genes expression with TNBC signature genes (ERBB2, ESR1, 
and PGR) from The Cancer Genome Atlas database was analyzed with the Cluster and 
TreeView program (106). Briefly, for any set of PARP1-associated kinases, an upper-
diagonal similarity matrix was computed by using average-linkage clustering. This 
algorithm was determined by computing a dendrogram. The heat map was represented 
graphically by coloring each cell on the basis of the measured fluorescence ratio. Log 
ratios of 0 (a ratio of 1.0 indicates that the genes are unchanged) were colored in black, 
positive log ratios were colored in red, and negative log ratios were colored in green. 
2.7 Confocal Microscopy Analysis of γ-H2AX Foci 
The assay was performed as previously described (105). Cells grown on chamber 
slides (Labtek, Scotts Valley, CA) were treated as described in the text. After washing 
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with ice-cold PBS, cells were fixed, permeabilized, and incubated with γ-H2AX 
antibodies and fluorescence-labeled secondary antibodies. Immunostained cells were 
examined by Zeiss LSM 710 laser-scanning microscope (Carl Zeiss, Thornwood, NY) 
with a 63X/1.4 objective. The ZEN and AxioVison (Carl Zeiss) software programs (NIH, 
Bethesda, MD) were used for data analysis. 
2.8 Comet Assay 
Comet assay was performed following procedure described previously with some 
modifications (107). Briefly, cells were sandwiched in agarose and subjected to 
electrophoresis in either alkaline electrophoresis buffer (0.3 N NaOH, 1 mM EDTA) or 
neutral electrophoresis buffer (0.3M Sodium acetate and 0.1M Tris-Cl, adjusted to pH 
8.3). To prepare gel sandwich, basal layer was made by applying 1.2% agarose in PBS to 
frosted microscope slide. Second layer is made of mixing equal amount of cell 
suspensions (106 cells/ml in PBS) with 1.2% low gelling temperature agarose. Third layer 
is made of 1.2 % low gelling temperature agarose. After gel sandwich solidified, the 
slides were immersed in ice-cold lysis buffer (2.5 M NaCl, 100 mM EDTA, 10 mM Tris-
Cl (pH 10), 1 % N-laurylsarcosine, 0.5 % Triton and 10 % DMSO) and stored at 4˚C for 
at least 2 hours. For alkaline comet assay, slides were immersed in alkaline 
electrophoresis buffer for 20 mins at 4˚C before electrophoresis at 20 V, 0.3 A for 25 
mins. While for neutral comet assay, slides were immersed in neutral electrophoresis 
buffer for 1 hour at 4˚C before electrophoresis at 14 V, 0.01 A for 1 hour. After 
electrophoresis, slides were stored in 0.4 M Tris-Cl (pH 7.5) before staining DNA with 
propidium iodide. The slides were subjected to examination with fluorescence 
microscope and image of at least 50 cells per treatment was recorded and the migration of 
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DNA was quantified by CometScore (TriTek Corp.) by the parameter of percentage of 
DNA in tail (%T). 
 
2.9 Duolink Assay  
Cells were prepared for fluorescence microscopy analysis. Primary antibodies 
were incubated with cells and a pair of oligonucleotide-labeled antibodies (PLA probes). 
Ligation and amplification were done according to the manufacturer's instructions 
(Duolink Assay Kit, Sigma-Aldrich) before mounting the slide for measurement under 
confocal microscope. The mean ± s.d. of PLA signal intensity from 50 cells in each 
treatment group was calculated. 
2.10 MTT Assay 
Cells were seeded at 1,500 cells/well in a 96-well plate overnight, then treated 
with indicated inhibitors at various concentrations for 72 hours. Then cells were 
incubated in 100 µL of sterile MTT (0.5 mg/mL; Sigma) for 2 hours at 37°C, followed by 
removal of the culture medium and addition of 100 µL of dimethyl sulfoxide. Absorbance 
was measured by fluorescent plate readers at spectra of 560 nm excitation/590 nm 
emission. Survival curves were expressed as mean ± s.d. relative to DMSO-treated 
control from three independent experiments. 
 
2.11 Clonogenic Cell Survival Assay  
Cells were plated into 6- or 12-well plates for overnight incubation, and then cells 
were treated with indicated inhibitors followed by 8 days of incubation. The colonies 
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were fixed and stained with 0.5% crystal violet, washed, dried and imaged. The number 
of colonies were quantified by ImageJ.  
 
2.12 Dual-Drug Combination Assay 
Cell growth of different treatment as indicated in text was measured by MTT 
assay or clonogenic cell survival assay. Synergistic effects of multiple drugs were 
determined by Chou and Talalay method to calculate the combination index (CI) using 
the software Calcusyn (108). CI values of <1, 1, and >1 indicate synergistic, additive, and 
antagonistic effects, respectively. 
 
2.13 In Vitro Kinase Assay 
For c-Met and PARP1 study, recombinant glutathione S-transferase (GST)-WT 
PARP1 (Ala374-Trp1014 of human PARP1) and mutants (GST-Y907F and GST-Y986E) 
were expressed by induction of isopropyl β-D-1-thiogalactopyranoside (IPTG) and 
purified with glutathione agarose beads. After cold-PBS washing three times, beads were 
suspended with 500 µl 1X kinase buffer, with 50 µl saved for western blotting with GST. 
The beads were spun down and 100 µM ATP, 0.5 µg human recombinant active c-Met 
protein and 50 µCi [γ-32P]-ATP were added in 50 µl kinase buffer at 30 °C for 15–30 min. 
For CK2 and PARP1 study, recombinant His-PARP1 (Sino Biological, #11040-H08B-
20) and His-CK2α (Life Technologies, #PV3248) were incubated in 1X kinase buffer 
with 100 µM ATP and 50 µCi [γ-32P]-ATP at 30 °C for 30 min. The kinase reaction was 
stopped by heating at 100 °C for 10 min in SDS loading dye. All samples were subjected 
to two identical SDS-PAGE assays. One was used for coomassie blue staining of total 
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proteins. The second gel was dried and used to detect phosphorylation of substrate by 
autoradiography. 
 
2.14 Cell Cycle Analysis 
Determination of cell cycle distribution was performed by BD FACS Canto II 
(BD Biosciences) and analyzed by FlowJo. Cells were treated with DMSO or indicated 
doses of inhibitos for 72 hours, cells were collected, washed with PBS, and fixed with 
75% ethanol for at least overnight at -20 °C. Fixed cells were collected by centrifugation 
and washed with PBS to discard ethanol. Cells were resuspended in 500 µl PBS 
containing 400 µg/ml propidium iodide (PI) and 0.2 mg/ml RNAase and incubated in 
37°C for 15 min. The stained cells were stored in 4 °C and detected on flow cytometer 
within 48 hours. 
 
2.15 Mouse Xenograft Model  
All animal procedures were conducted under the approval of the Institutional 
Animal Care and Use Committee (IACUC) at The University of Texas MD Anderson 
Cancer Center (protocol number 10-14-07231). MDA-MB 231 (5×105), HCC1937 
(2×106) cells and BT549 (5×106) cells were injected into the mammary fat pads of female 
nude mice (Swiss Nu/Nu) of 6–8 weeks of age (Department of Experimental Radiation 
Oncology Breeding Core, The University of Texas MD Anderson Cancer Center). When 
the tumor volume reached ~50 mm3, mice were treated with vehicle, crizotinib (5 mg/kg, 
p.o) and foretinib (5 mg/kg, p.o), AG-014699 (5 mg/kg, p.o) and ABT-888 (25 mg/kg, 
p.o) were administered to mice five times per week as single agents or in combination for 
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the number of days specified in the figure legends; while AZD-2281 (25 mg/kg, p.o) and 
CX-4945 (6.25 mg/kg, i.p) were administered to mice daily as single agents or in 
combination for two weeks. Tumor was measured at the indicated time points, and tumor 
volume was calculated by the formula length × width2 × ½. Tumors were not allowed to 
grow larger than allowed by the animal welfare protocol. 
2.16 Statistical Analysis  
Each sample was assayed in triplicate in this study. For in vitro analysis, each 
experiment was repeated at least three times. All error bars represent standard deviation 
(s.d.). Student's t test was used to compare two groups of independent samples. Repeated-
measures ANOVA analysis was used to evaluate the statistical significance of dose curve 
response. Correlations were analyzed using the Pearson chi-square test. A P value of < 
0.05 was considered statistically significant. No statistical methods were used to 
determine sample size.  
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CHAPTER 3  
RESULTS 
Figures 3.1 to 3.5 are obtained and modified by permission from the Nature publishing 
group: Yi Du, Hirohito Yamaguchi, Yongkun Wei, Jennifer L Hsu, Hung-Ling Wang, 
Yi-Hsin Hsu, Wan-Chi Lin, Wen-Hsuan Yu, Leonard, Gilbert R Lee IV, Mei-Kuang 
Chen, Katsuya Nakai, Ming-Chuan Hsu, Chun-Te Chen, Ye Sun, Yun Wu, Wei-Chao 
Chang, Wen-Chien Huang, Chien-Liang Liu, Yuan-Ching Chang, Chung-Hsuan Chen, 
Morag Park, Philip Jones, Gabriel N Hortobagyi  & Mien-Chie Hung. Blocking c-Met–
mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. 
Nature Medicine, 2016, 22(2), 194-201(105)  
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Results 
3.1 ROS Levels is Associated with PARP1 Activity in TNBC  
3.1.1 TNBCs Showed Higher Oxidative DNA Damage and ROS Levels in 
TNBCs than Non-TNBCs 
Reactive oxygen species (ROS) levels are higher in multiple types of cancer cells 
compared with normal cells (109), and a high level of ROS scavenger enzymes has been 
correlated with good prognosis in TNBC (110). ROS is a major resource for inducing 
oxidative DNA damage. Therefore, first we asked whether oxidative DNA damage and 
ROS levels were higher in TNBCs compared to non-TNBCs. We examined cellular 8-
hydroxydeoxyguanosine (8-OHdG), an oxidative DNA damage marker to determine the 
DNA damage levels in multiple TNBC cells by immunofluorescence staining (Figure 
3.1.1.1). For ROS levels, we detected the ROS marker 2′,7′-dichlorofluorescein (DCF) by 
fluorescence microscope (Figure 3.1.1.2). After data analysis, we found that 8-OHdG and 
DCF signals were higher in TNBC cell lines than in non-TNBC cell lines. Together, these 
results indicate that oxidative DNA damage and ROS levels in TNBC were higher than 
the ones in non-TNBC.  
 
  
	 31	
 
 
Figure 3.1.1.1 TNBC Cell Lines Showed Higher Oxidative Damage DNA than Non-
TNBC Cell Lines 
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Figure 3.1.1.1 TNBC Cell Lines Showed Higher Oxidative Damage DNA than Non-
TNBC Cell Lines 
(A) A panel of breast cancer cell lines was stained with 8-OHdG antibody and 
immunofluorescence signals were detected by fluorescence microscope. Red, 8-
OHdG; Blue, DAPI. Bar, 20 µm. 
(B) Quantification of the fluorescence intensity signals by AxioVision software was 
shown.  
Experiments in figure 3.1.1.1 were conducted by Yi Du.  
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Figure 3.1.1.2 TNBC Cell Lines Showed Higher ROS Levels than Non-TNBC Cell 
Lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) The DCF signals and differential interference contrast (DIC) images of various 
breast cancer cells. DCF signals (green) were detected by fluorescence 
microscope. Bar, 100 µm. 
(B) Quantification of fluorescence intensity by AxioVision software was shown. 
Experiments in figure 3.1.1.2 were conducted by Yi Du.   
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3.1.2 PARP1 Activity is Higher in TNBCs than Non-TNBCs 
PARP1 is the key molecular for ROS-induced DNA damage repair. Our previous 
data showed that ROS level is higher in TNBC than non-TNBC. Next, we asked whether 
PARP1 activity was higher in TNBC than non-TNBC cell lines. We determined 
poly(ADP)-ribose (PAR) levels, which represent cellular PARP activity, by western blot 
in a panel of TNBC and non-TNBC cell lines. Indeed, PAR expression was higher in 
TNBC cell lines compared to non-TNBC cell lines (Figure 3.1.2). These data suggest that 
PARP activity in TNBC is higher than that in non-TNBC. Together with the results from 
Figure 3.1.1, these data suggest that there may be positive association between ROS and 
activity of PARP in TNBC.  
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Figure 3.1.2 PARP1 Activity is Higher in TNBC cell lines than Non-TNBC cell lines 
 
 
 
 
 
 
 
Immunoblot showing the expression of PAR and PARP1 in a panel of breast cancer cells. 
LAR, luminal androgen receptor. ER, estrogen receptor; HER2, human epidermal growth 
factor receptor 2. 
Experiments in figure 3.1.2 were conducted by Yi Du and Wen-Hsuan Yu. 
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3.2 ROS Induce the Association of c-Met and PARP1 
3.2.1 c-Met Interacts with PARP1 upon ROS Stimulation 
Next, we investigated the molecular mechanism regulating PARP activity under 
ROS-induced DNA damage. We searched for PARP1 interacting proteins, especially 
tyrosine kinases (TKs) since many of them are druggable targets, which will make the 
future clinical application easier. Furthermore, it is known that ROS activate receptor 
tyrosine kinases (RTKs) (111). Therefore, we used phospho-RTK antibody array to 
screen PARP1 associated TKs in the cells treated with sodium arsenite (As), a ROS 
inducer (data not shown).  Also, we are interested in the target, which overexpressed in 
TNBC. According to the criteria, we first focused on c-Met, which gave the highest score 
of PARP1 interaction upon ROS stimulation.  
We further verified the association between c-Met and PARP1 by co-
immunoprecipitation (Co-IP). MDA-MB 231 and HCC1937 cells, and 293T cells 
overexpressing c-Met and PARP1 were stimulated with H2O2 and subjected to Co-IP 
(Figure 3.2.1). The data demonstrate that c-Met indeed interacts with PARP1 upon ROS 
stimulation. 
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Figure 3.2.1 c-Met Interacts with PARP1 upon ROS Stimulation 
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Figure 3.2.1 c-Met Interacts with PARP1 upon ROS Stimulation 
(A)(B) MDA-MB 231 cells (A) and HCC 1937 cells (B) were treated with 20 mM 
H2O2 treatment for 30 min and subjected to Co-IP with anti-c-Met antibody, 
followed by western blot to detect the interaction of PARP1 and c-Met.  
(C) HEK 293T cells transfected with V5-PARP1 and Flag-c-Met were treated with 
10 mM H2O2 for 15 min and subjected to Co-IP with anti-Flag tag or anti-V5 tag 
antibodies, followed by western blot with the indicated antibodies. 
Experiments in figure 3.2.1 were conducted by Yi Du.  
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3.2.2 The Interaction between c-Met and PARP1 is Mainly in the Nucleus 
upon ROS Stimulation 
 c-Met and PARP1 are known to be mainly located in cell surface membrane and 
the nucleus, respectively. However, it has been reported that c-Met can translocate into 
the nucleus (112). Therefore, we asked where the interaction between c-Met and PARP1 
occurs. To address this question, we performed cell fractionation with Co-IP analysis and 
Duolink assay. Co-IP using nuclear/cytoplasmic fractions showed that the interaction 
between c-Met and PARP1 occurred in both the cytoplasmic and nuclear fractions, and 
that the interaction was enhanced by H2O2 treatment in MDA-MB 231 with ectopic 
expression of HA-tagged PARP1 (Figure 3.2.2 A). Duolink assay further verified the 
results that c-Met and PARP1 interactions primarily in nucleus (Figure 3.2.2 B). Together, 
these data suggest that c-Met translocates into the nucleus and interacts with PARP1 
upon ROS stimulation. 
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Figure 3.2.2 The Interaction between c-Met and PARP1 is Mainly in the Nucleus 
upon ROS Stimulation 
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Figure 3.2.2 The Interaction between c-Met and PARP1 is Mainly in the Nucleus 
upon ROS Stimulation 
 
(A) MDA-MB-231 cells with ectopic expression of HA-tagged PARP1 were treated 
with 20 mM H2O2 for 30 min and with or without a 1-hour pre-treatment with 2 
µM crizotinib (Cri). The interaction of PARP1 and c-Met in cytosolic and nuclear 
fractions by Co-IP/Western blot. S, short exposure. L, long exposure. 
(B) Proximity ligation assay to detect co-localization of PARP1 and c-Met in MDA-
MB 231 cells treated with 20 mM H2O2 or 20 µM sodium arsenite (AS). 
Quantification of PLA signals from 50 cells was shown in the right panel. Bar, 20 
µm. 
Experiments in figure 3.2.1 were conducted by Yi Du.  
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3.3 Inhibition of c-Met Sensitizes TNBC Cells to PARP Inhibitor 
3.3.1 Knockdown of c-Met Enhances the Sensitivity to PARP Inhibitor in 
TNBC Cells 
We showed that c-Met could interact with PARP1. Therefore, we hypothesized 
that c-Met may regulate PARP1 activity and affect tumor the response to PARPi. To test 
this hypothesis, we knocked down c-Met in MDA-MB 231 by shRNA and treated the 
cells with different PARPi including olaparib (AZD-2281), rucaparib (AG-014699) and 
veliparib (ABT-888). We then evaluated the role of c-Met under PARP inhibition by 
MTT assay (Figure 3.3.1 A) and soft agar assay (Figure 3.3.1 B). The results with 
different assays showed that knockdown of c-Met sensitized MDA-MB 231 to PARPi in 
MTT assay and soft agar assays. We also knocked down c-Met in HCC-1937 cells, which 
have BRCA1 mutation but are resistant to PARPi. These cells also became more sensitive 
to PARPi after knockdown of c-Met (Data not shown).  These data suggest that c-Met 
contributes to the PARPi resistance in TNBC. 
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Figure 3.3.1 Knockdown of c-Met Enhances the Sensitivity to PARP Inhibitor in 
TNBC Cells  
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Figure 3.3.1 Knockdown of c-Met Enhances the Sensitivity to PARP Inhibitor in 
TNBC Cells  
 
(A) Western blot of c-Met showing shRNA efficiency in MDA-MB 231 cells (upper 
panel). c-Met-knockdown MDA-MB 231 cells were treated with the different 
concentration of AG-014699, and subjected to MTT assay. IC50 of AG-014699 
was shown in the right panel. 
(B) c-Met-knockdown MDA-MB 231 cells were treated with ABT-888, and 
subjected to soft agar colony formation assay. Quantification of colony number 
was shown in right panel. 
Experiments in figure 3.3.1 were conducted by Yi Du, Hirohito Yamaguchi and Wen-
Hsuan Yu. 
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3.4 c-Met Phosphorylates PARP1 at Tyrosine 907 (Y907) and Increases Its 
Function. 
 3.4.1 c-Met Phosphorylates PARP1 at Y907 
Our previous data demonstrated that c-Met physically associated with PARP1 and 
also inhibition of c-Met sensitized TNBC to PARPi. Therefore, we hypothesized that c-
Met could phosphorylate PARP1 under oxidative stress. We first used software 
(NetworKIN 2.0) to predict the potential tyrosine residues in PARP1 that is 
phosphorylated by c-Met.  Tyrosine 907 (Y907), which located on the H-Y-E motif in the 
catalytic domain of PARP1, was predicted as a potential phosphorylation site.  
 Using recombinant PARP1 proteins with/without the mutation in Y907 (tyrosine 
to phenylalanine, Y907), we verified Y907 phosphorylation by c-Met by in vitro kinase 
assay (Figure 3.4.1.1). We also raised the specific antibody against p-Y907 of c-Met, and 
demonstrated that in response to ROS stimulation, PARP1 is phosphorylated (Figure 
3.4.1.2 A). Moreover, the phosphorylation of PARP1 at Y907 is abolished in c-Met-
knockdown MDA-MB 231 cells (Figure 3.4.1.2 B). Together, these data suggest that c-
Met mediates phosphorylation of PARP1 at Y907 in vivo.  
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Figure 3.4.1.1 c-Met Phosphorylates PARP1 at Y907 by in vitro Kinase Assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Left panel, coomassie blue staining of GST fusion wild-type PARP1 and PARP1 Y907F 
and Y986F mutants. Right panel, In vitro kinase assay, GST fusion wild-type PARP1 and 
PARP1 Y907F and Y986F mutants were incubated with purified c-Met in kinase buffer 
in the presence of [γ-32P]-ATP. Phosphorylated PARP1 was measure by 
autoradiography.   
Experiments in figure 3.4.1 were conducted by Yi Du, Hung-Ling Wang and Wei-Chao 
Chang. 
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Figure 3.4.1.2 c-Met Phosphorylates PARP1 at Y907 upon ROS Stimulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Immunoblot showing the expression of pY907-PARP1. MDA-MB 231 wild type 
and PARP1-knockdown cells were treated with 20 mM H2O2 for 30 min, and 
subjected to western blot with the indicated antibodies.  
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(B) Immunoblot showing the expression of pY907-PARP1. MDA-MB 231 wild type 
and c-Met-knockdown cells were treated with 20 mM H2O2 for 30 min, and 
subjected to western blot with the indicated antibodies.  
Experiments in figure 3.4.1.2 were conducted by Yi Du, Hung-Ling Wang, Wan-Chi 
Lin and Wen-Hsuan Yu. 
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3.4.2 Phosphorylation of PARP1 at Y907 Enhances PARP1 Activity 
  Next, we further investigated whether PARP1 Y907 phosphorylation contributes 
to PARP function and PARPi resistance.  To address this question, we stably re-
expressed WT, Y907F (non-phosphorylatable) or Y907E (phosphomimetic)-mutant 
PARP1 in PARP1-knockdown MDA-MB 231 cells, and used these stable cells for 
various assay. First, we determined DNA damage repair ability in these stable cell lines 
by comet assay. The data showed that the cells expressing Y907F PARP1 exhibited more 
DNA strand breaks than the one expressing wild type PARP1, while the cells with 
Y907E did lower than the one with wild type (Figure 3.4.2 A). Second, we evaluated 
PARP activity by measuring the expression of PAR and Y907F PARP1 showed less 
PARP activity than wild type PARP1, while Y907 did higher than wild type one (Figure 
3.4.2 B). Moreover, the cells expressing Y907F PARP1 were more sensitive to PARPi 
than the cells expressing wild type, while the cells with Y907E PARP1 were more 
resistant to PARPi than the one with wild type PARP1 by colony formation assay (Figure 
3.4.2 C). Together, these findings supported our hypothesis that phosphorylation of 
PARP1 at Y907 contributes to PARP activity and attenuates the response to PARPi in 
TNBC.  
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Figure 3.4.2 Phosphorylation of PARP1 at Y907 Contributes to PARP Function and 
PARP Inhibitor Resistance  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) DNA strand breaks were measured by comet assay with pre-incubation with 
formanidopyrimidine DNA glycosylase (Fpg) in PARP1-WT-, PARP1-Y907E-, 
or PARP1-Y907F-expressing MDA-MB 231 stable cells treated with 20 mM 
H2O2 for 30 min. Immunoblot showing expression of PARP1 in PARP1-
knockdown MDA-MB 231 cells and WT PARP1 or the Y907 mutant re-
expressing MDA-MB 231 cells. The quantified intensity of damaged DNA was 
shown in right panel. Bar, 100 µm. 
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Figure 3.4.2 Phosphorylation of PARP1 at Y907 Contributes to PARP Function and 
PARP Inhibitor Resistance  
(B) Immunoblot showing PAR expression in the MDA-MB 231 stable cells as 
described in (A) with or without 20 mM H2O2 for 30 min. 
(C) MDA-MB 231 stable cells as described in (A) were treated with indicated 
concentration of AG-014699 and subjected to clonogenic formation assay for 8 
days. Bar, 10 mm. *P < 0.05, Student’s t-test. n.s., not significant.  
Experiments in figure 3.4.2 were conducted by Yi Du, Hirohito Yamaguchi, Wan-Chi 
Lin, Wen-Hsuan Yu, Mei-Kuang Chen and Katsuya Nakai. 
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3.5 The Clinical Relevance of c-Met and Phosphorylation of PARP1 at Y907 
3.5.1 c-Met and p-Y907 PARP1 Expression is Positively Correlated in TNBC 
To investigate the clinical significance of our findings, we performed IHC 
staining with p-Y907 and c-Met antibodies in TNBC tissue microarray. The results 
demonstrated a positive correlation between c-Met and p-Y907 PARP1 (Figure 3.5.1).  
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Figure 3.5.1 The Correlation between c-Met and p-Y907 PARP1 is Positive in TNBC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Representative images of immunohistochemical staining for pY907-PARP1 and c-Met 
from tissue microassay of TNBC (77 cases). Bar, 100 µm.  
Experiments in figure 3.5.1 were conducted by Yi Du and Yongkun Wei.  
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3.5.2 The Combination of c-Met and PARP Inhibitor Has Synergistic Effect 
in TNBC Cells in vitro and in vivo 
Finally, we examined the therapeutic efficacy of the combination of METi 
(foretinib and crizotinib) and PARPi (ABT-888 and AG-014699). We performed the 
dual-drug combination analysis in MDA-MB 231 and HCC 1937 by MTT assay and 
clonogenic cell survival assay. Using combination index (CI), we evaluated synergistic 
effects. The results showed that the combination exhibited synergistic inhibition of cell 
growth in TNBC cell lines (Figure 3.5.2.1).  
We then evaluated the combination effect in MDA-MB 231 xenograft mice model. 
The combination treatment (AG-014699-crizotinib and ABT-888-foretinib) substantially 
reduced tumor growth compared to either inhibitor alone or vehicle (Figure 3.5.2.2). 
Thus, this combination is effective against TNBC both in vitro and in vivo, suggesting 
METi and PARPi serve as an effective therapeutic strategy to treat TNBC with c-Met 
overexpression.  
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Figure 3.5.2.1 The Combination of c-Met and PARP Inhibitor Has Synergistic 
Effect in TNBC Cells in vitro 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) CI plots of the combination of AG-014699 (AG) and crizotinib (Cri) or ABT-888 
(ABT) and foretinib (Ft) in both MDA-MB 231 and HCC 1937. 
(B) The synergistic effect of crizotinib and AG-014699 in MDA-MB 231 cells and 
HCC1937 cells was measured by soft agar assay after a 4-week treatment. 
Quantification of relative colony numbers and CI values was shown.  
Experiments in figure 3.5.2.1 were conducted by Yi Du, Hirohito Yamaguchi and 
Wen-Hsuan Yu. 
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Figure 3.5.2.2 The Combination of c-Met and PARP Inhibitor Has Synergistic 
Effect in TNBC Cells in vivo 
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Figure 3.5.2.2 The Combination of c-Met and PARP Inhibitor Has Synergistic 
Effect in TNBC Cells in vivo 
(A) MDA-MB 231 cells were inoculated into the mammary fat pads of nude mice (10 
mice per group). When the tumor reached ~50 mm3, mice were orally 
administered AG-014699 (10 mg/kg), crizotinib (5 mg/kg), or the combination 
five times per week. Tumor volume was measured at the indicated time points. 
*P < 0.05, Student’s t-test. 
(B) Same as (A), but the mice were orally treated with ABT-888 (25 mg/kg), 
foretinib (5 mg/kg), or the combination.  
Experiments in figure 3.5.2.2 were conducted by Yi Du, Hirohito Yamaguchi, Wan-
Chi Lin, Wen-Hsuan Yu, Mei-Kuang Chen and Chun-Te Chen. 
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3.6 CK2 is The Potential PARP1 Regulator 
3.6.1 Identification of Druggable PARP1-Associated Serine/Threonine 
Kinase in TNBC by Bioinformatics Analysis of Public Database and Mass 
Spectrometry Data  
In addition to tyrosine kinases, previous studies have shown that multiple 
serine/threonine (S/T) residues within important regulatory domains and motifs in 
PARP1 are phosphorylated by kinases (56). To identify other S/T kinases that are 
involved in the regulation of PAPR1, first we screened potential PARP1-associated S/T 
kinases from online databases and published mass spectrometry databases (56, 113) as 
well as our own mass spectrometry analysis data of PARP1 binding proteins. We 
identified thirteen S/T kinases that potentially interact with PARP1 (Table 3.1). Then, we 
analyzed the patient samples from TCGA database (The Cancer Genome Atlas) to select 
genes that are overexpressed in TNBC compared with other subtypes of breast cancer 
(Figure 3.6.1). From the data, we found six out of thirteen PARP1-associated S/T kinases 
overexpressed in TNBC. Furthermore, we especially focused on the S/T kinases whose 
inhibitors are currently used in the clinic or in clinical trials, and therefore could be 
readily tested in combination in clinical trials. Based on the above criteria, CDK2, PKCβ 
and CK2 are three candidates for PARP1 regulators (Table 3.2).  
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Table 3.1 Thirteen PARP1-Associated S/T Kinases 
 
Kinase Entrez gene name  
CDK8 Cyclin-dependent kinase 8 BioGRID Database 
MAPK13 Mitogen-activated protein kinase 13 BioGRID Database 
ERK1/2 Mitogen-activated protein kinase 1  (56, 57) 
CDK5 Cyclin-dependent kinase 5 (56, 114) 
CDK2 Cyclin-dependent kinase 2 (115) 
JNK1 c-jun N-terminal kinase (56, 58) 
CaMK-II Calcium/calmodulin-dependent protein kinase II  (56, 116) 
PKCβ Protein kinase C, beta (56, 117) 
AMPKα2 protein kinase, AMP-activated, alpha 1 catalytic subunit (56) 
PKA Protein kinase, cAMP-dependent, catalytic, alpha (113) 
CK2 Casein Kinase 2 (113)  Our Mass Spec data 
ZAK Mitogen-activated protein kinase kinase kinase MLT Our Mass Spec data 
WNK1 Serine/threonine-protein kinase WNK1 Our Mass Spec data 
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Figure 3.6.1 Expression of Six PARP1-Associated S/T Kinases mRNA Correlates 
with TNBC from TCGA Database 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Hierarchical clustering analysis of mRNA expression six PARP1-associated S/T 
kinases and breast cancer markers in TCGA database. Red represents high gene 
expression, and green represents low gene expression.  
(B) Box plot generated from original and log2-tranformed mRNA expression levels 
of thirteen PARP1-associated S/T kinases. The genes highlighted in red correlate 
with TNBC.  
A B 
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 Table 3.2 Three Druggable PARP1-Associated S/T Kinases  
Kinase Entrez gene name Drugs Clinical Trials 
CDK2 Cyclin-dependent kinase 2 
SNS-032, Sunesis 
Pharmaceuticals 
Phase I trials in select 
advanced solid tumors 
PKCβ Protein kinase C, beta 
Sotrastaurin(AEB071), 
Norvatis 
PhaseIb/II in uveal 
melanoma 
CK2 Casein Kinase 2 CX-4945, Cylene, Senhwa Biosciences 
Phase1/2 in 
cholangiocarcinoma 
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3.6.2 Dual-Drug Combination Effect of CDK2, PKCβ, CK2 and PARP 
Inhibitors in TNBC cells 
Next, we performed dual-drug combination assay to further investigate the anti-
TNBC efficacies of combination of a CDK2 inhibitor (SNS-032), a PKCβ inhibitor 
(sotrastaurin), a CK2 inhibitor (CX-4945) and four PARPi (olaparilb [AZD-2281], 
Veliparib [ABT-888], talazoparib [BMN-673], and rucaparib [AG-014699]). We first 
determined IC50 of each drug in MDA-MB 231 and BT549 cell lines by MTT assay. 
Then, we performed the combination index (CI) theorem of Chou-Talalay to offer a 
quantitative definition for the addictive effect (CI = 1), synergism (CI < 1), and 
antagonism (CI > 1) in dual-drug combinations to test synergistic efficacy as determined 
by MTT assay. 
As shown in Figure 3.6.2.1, MDA-MB 231 treated with CX-4945, SNS-032, 
sotrasaturin, and four different PARP inhibitors alone or in combination at various 
concentrations. CI-Fa (fraction affected) values as a function of fractional inhibition were 
plotted to determine drug interactions by computer simulation (CompuSyn). For example, 
a fixed ratio of BMN-673 and CX-4945 combination (BMN-673/CX-4945 = 10:1) was 
determined by the IC50s of the individual drugs. The CI-Fa plot of this combination 
showed that the strongest synergism at 97% ED (effective dose) with CI value of 0.49 in 
MDA-MB 231 cells. However, the combination of BMN-673 and sotrasaturin or SNS-
032 at 97% ED were antagonism with CI above 1. Therefore, the combination with the 
best therapeutic effect among three kinase inhibitors with BMN-673 was CX-4945. We 
performed the same analysis for all dual-drug combinations in BT549 (Figure 3.6.2.2). 
The CI values of dual-drug combinations in the different cell lines were summarized as 
	 64	
Table 3.3. According to these results, the best synergism was observed in the 
combination of CX-4945 with PARPi (BMN-673 and AZD-2281) in MDA-MB231 and 
BT549 at 97% EDs with CI value of 0.49 and 0.31, respectively. CX-4945 is a CK2 
inhibitor, and therefore CK2 may be a potential kinase to regulate PARP1.  
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Figure 3.6.2.1 The Effect of Dual-Drug Combinations of Kinase Inhibitors and 
PARP Inhibitors in MDA-MB 231 
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Figure 3.6.2.1 The Effect of Dual-Drug Combinations of Kinase Inhibitors and 
PARP Inhibitors in MDA-MB 231 
 
CI plots for the dual drug combinations of PARPi (AZD-2281, AG-014699, ABT-888 
and BMN-673) and kinase inhibitors (CX-4945, SNS-032 and sotrastaurin) in MDA-MB 
231. Cells were treated with the combinations at various concentrations for 72 hours. CI 
values were plotted as a functional of fractional inhibition as determined by MTT assay. 
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Figure 3.6.2.2 The Effect of Dual-Drug Combinations of Kinase Inhibitors and 
PARP Inhibitors in BT549 
 
  
BT549 cells were used for the same assay described in Figure 3.6.2.1.   
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Table 3.3 Summary of CI Values of Dual-Drug Combinations in TNBC Cell Lines 
 
 
CI 
Drug combination ED50 ED75 ED90 ED97 
MDA-MB 231 
CX/AZD 1.01 1.11 1.25 1.45 
CX/AG 1.23 1.09 0.98 0.86 
CX/ABT 1.05 0.88 0.75 0.63 
CX/BMN 0.71 0.60 0.53 0.49 
 SNS-AZD 0.96 1.22 1.66 2.61 
SNS-AG 1.26 1.50 1.78 2.17 
SNS-ABT 0.97 1.29 1.73 2.43 
SNS-BMN 0.77 0.76 0.90 1.10 
 SO/AZ 0.33 0.82 2.41 8.58 
SO/AG 1.01 0.80 0.67 0.58 
SO/ABT 1.06 1.10 1.69 3.50 
SO/BMN 2.52 264.25 39643.70 16130000.00 
BT549 
CX/AZD 1.06 0.65 0.45 0.31 
CX/AG 1.59 1.51 1.43 1.35 
CX/ABT 0.85 0.83 0.84 0.86 
CX/BMN 0.85 0.66 0.76 0.89 
 SNS-AZD 1.03 0.74 0.65 0.68 
SNS-AG 0.94 0.91 0.90 0.89 
SNS-ABT 0.78 0.90 1.11 1.51 
SNS-BMN 0.50 1.14 2.91 8.67 
 SO/AZD 0.71 0.74 1.39 3.36 
SO/AG 1.09 0.91 0.75 0.61 
SO/ABT 1.12 1.40 1.76 2.30 
SO/BMN 0.83 25.94 830.79 46999.70 
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3.6.3 The Protein Expression of CK2 in Breast Cancer Cell Lines 
From the previous TCGA data analysis, we found that the mRNA level of CK2 is 
significantly correlated with TNBC. Therefore, we wondered whether the protein level of 
CK2 is also overexpressed in TNBC. To address this question, we selected a panel of 
breast cancer cell lines to examine the protein expression level of CK2. Generally, we 
found that all the breast cancer cell lines expressed both CK2α and CK2β. However, 
TNBC expressed higher amount of CK2α protein compared to non-TNBC by 
immunoblotting assay. 
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Figure 3.6.3 Expression of CK2 Protein Correlates with TNBC Cell Lines 
Immunoblot showing the protein expression of CK2α and CK2β in a panel of breast 
cancer cell lines. 
LAR, luminal androgen receptor. ER, estrogen receptor; HER2, human epidermal growth 
factor receptor 2. 
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3.7 Inhibition of CK2 Sensitizes TNBC Cells to PARP Inhibitor 
3.7.1 The Combination of CK2 and PARP Inhibitors Has Synergistic Effect 
in TNBC  
Knowing that the combination with the strongest synergism is CK2 and PARPi 
and also CK2 is overexpressed in TNBC, we asked whether the dual-drug combinations 
affect on the tumorigenic potential of TNBC cells. To address this question, first we 
performed dual-drug combination assay in TNBC cells by colony formation assay. The 
result showed that inhibition of CK2 by CX-4945 rendered MDA-MB 231 cells more 
sensitive to all four PARPi, as indicated by inhibiting colony forming (Figure 3.7.1.1). 
The relative number of colonies were quantified by ImageJ. For example, AG-014699 
alone at 0.8 µM resulted in ~35% colony formation inhibition; while CX-4945 alone at 
0.4 µM resulted in ~10% colony formation inhibition. Addition of both AG-014699 and 
CX-4945 at a fixed drug ratio (0.4uM AG-014699/ 0.8uM CX-4945) resulted in ~65% 
colony formation reduction that was shown to be synergism by calculating CI value 
(CI=0.58) with the Chou and Talalay method (Figure 3.7.1.1 A). Data analysis indicated 
that the CI values of different combinations of CX-4945 and PARPi are all below 1 in 
MDA-MB 231. Synergistic inhibition of CX-4945 and PARPi was also observed in 
BT549 by clonogenic cell survival assay (Figure 3.7.1.2). Consistent with cell 
proliferation MTT assay, these data suggested CX-4945 and PARPi show synergy with 
PARPi.  
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Figure 3.7.1.1 The Combination of CK2 and PARP Inhibitors Has Synergistic Effect 
in MDA-MB 231  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) The effect of the combination of CK2i and PARPi was determined by clonogenic 
assay in MDA-MB 231. Cells were treated with AG-014699 (AG) and CX-4945 
(CX), alone or in combination at various concentrations as indicated for 8 days. CI 
value is quantified as previous described. The quantified result of visible colonies 
was shown in right panel. Error bars indicate the SD (n=3). 
(B) Same as (A) but cells were treated with AZD-2281 (AZ) and CX-4945 (CX). 
0 0.8 1.6 3.2 AG(µM) 
0 0.4 0.8 1.6 CX(µM) 
0 
0 
0.8/ 
0.4 
1.6/ 
0.8 
3.2/ 
1.6 
AG/ 
CX 
0.58 0.93 ?.53 
Combination Index (CI) 
CI
=0
.5
8	
CI
=0
.9
3	
CI
=0
.5
3	
0	
20	
40	
60	
80	
100	
120	
AG	 CX	 AG/CX	
Co
lo
ny
	ar
ea
	%
	
0 
0.
4 
0.
8 
1.
6 
CX(µM) 
 
0 
0.
8 
1.
6 
3.
2 
AG(µM) 
 
0 
0.
8/
0.
4 
1.
6/
0.
8 
3.
2/
1.
6 
AG/CX 
 
0 0.75 1.5 3 AZD(µM) 
0 0.4 0.8 1.6 CX(µM) 
0 
0 
0.75/ 
0.4 
1.5/ 
0.8 
3/ 
1.6 
AZD/ 
CX 
0.7 0.9 ?.39 
Combination Index (CI) 
CI
=0
.7
	
CI
=0
.9
	
CI
=0
.3
9	
0	
20	
40	
60	
80	
100	
120	
AZD	 CX	 AZD/CX	
Co
lo
ny
	ar
ea
	%
	
0 
0.
4 
0.
8 
1.
6 
CX(µM) 
 
0 
0.
75
 
1.
5 
3.
0 
AZD(µM) 
 
0 
0.
75
/0
.4
 
1.
5/
0.
8 
3.
0/
1.
6 
AZD/CX 
 
A	
B	
	 73	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(C) Same as (A) but cells were treated with ABT-888 (ABT) and CX-4945 (CX). 
(D) Same as (A) but cells were treated with BMN673 (BMN) and CX-4945 (CX). 
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Figure 3.7.1.2 The Combination of CK2 and PARP Inhibitors Has Synergistic Effect 
in BT549  
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Figure 3.7.1.2 The Combination of CK2 and PARP Inhibitors Has Synergistic Effect 
in BT549  
 
(A) Similar to (Figure 3.7.1.1) but BT549 cells were used in the assay. Cells were 
treated with AZD-2281 (AZ; 0.5 umol/L) and CX-4945 (CX; 1umol/L), alone or 
in combination for 10 days. 
(B) Same as (A) but cells were treated with AG-014699 (AG; 0.5 umol/L) and CX-
4945 (CX; 1umol/L). 
(C) Same as (A) but cells were treated with ABT-888 (ABT; 3.5 umol/L) and CX-
4945 (CX; 1umol/L). 
(D) Same as (A) but cells were treated with BMN-673 (BMN; 2 nmol/L) and CX-
4945 (CX; 2umol/L). 
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3.7.2 Knockdown of CK2 Enhances the Sensitivity to PARP Inhibitor in 
TNBC Cells 
 To further validate that CK2 influences the sensitivity to PARPi in TNBC, we 
used small interference RNA to knockdown CK2 and examined the colony forming 
ability after PARPi (AG-014699 and ABT-888) treatment. We knocked down CK2α and 
CK2α’, which are catalytic subunits of CK2 protein, because CX-4945 targets the activity 
of both CK2α and α’ (Figure 4.7.2 A). The results of colony formation assay showed that 
knockdown of both CK2α and CK2α’ significantly increased the PARPi (AG-014699) 
sensitivity in MDA-MB 231. This data suggests that CK2 contributes to PARPi 
resistance in TNBC cells.  
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Figure 3.7.2 Knockdown of CK2 Enhances the Sensitivity to PARP Inhibitor in 
TNBC cells 
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Figure 3.7.2 Knockdown of CK2 Enhances the Sensitivity to PARP Inhibitor in 
TNBC cells 
 
(A) CK2α and CK2α’ expression was determined by western blot to show siRNA 
efficiency in MDA-MB 231. 
(B) CK2α/α’ knockdown MDA-MB 231 cells were treated with the indicated 
concentrations of AG-014699 for 8 days and subjected to clonogenic cell survival 
assay. Quantification of clonogenic cells (n=3) was shown. *P < 0.05, Student’s 
t-test. 
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3.7.3 The Combination of CK2 and PARP Inhibitors Has Synergistic Effect 
in vivo 
Next, we evaluated the effect of the combination treatment of CK2i and PARPi in 
a TNBC xenograft mice model. In the BT549 xenograft tumor model, the mice were 
treated with AZD-2281 orally (25 mg/kg, p.o) and intraperitoneal injection of CX-4945 
(6.25mg/kg, i.p) alone, or in combination daily for 14 days. The mice tumor volume was 
measured every two days. Consistent with our previous findings from in vitro assays, the 
combination treatment was more effective in reducing tumor growth than was either 
alone treatment or vehicle control (p < 0.05) (Figure 3.7.3). The mice body weight 
remained almost the same after treatment.  
Together, the data from in vitro and in vivo studies suggested that CK2 
contributes to PARPi resistance and inhibition of CK2 enhances PARPi sensitivity in 
TNBC.  
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Figure 3.7.3 The Combination of CX-4945 and AZD-2281 Inhibits Tumor Growth 
in BT549 Orthotopic Xenograft Mice Model  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Representative images of xenograft BT549 tumors from each group as indicated. 
AZD, AZD-2281; CX, CX-4945; AZD/CX, AZD-2281 and CX-4945 
combination. 
(B) BT549 cells were inoculated into the mammary fat pads of nude mice (3 mice per 
group). When the tumor reached ~60 mm3, mice were administered AZD-2281 
(AZD, 25mg/kg, p.o), CX-4945 (CX, 6.25mg/kg, i.p), or the combination 
(AZD/CX) daily for 14 days. Tumor volume was measured at the indicated time 
points. *P < 0.05, Student’s t-test. 
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3.8 Mechanism of the Synergistic Effect of PARP Inhibitor and CK2 Inhibitor 
3.8.1 Inhibition of CK2 and PARP Increases DNA Strand Breaks  
We already showed that the combination of PARPi and CK2i has a synergistic 
effect in TNBC cells.  It is known that inhibition of PARP1 accumulates DNA strand 
breaks and results in DNA damage. Therefore, to establish the mechanism of PARPi 
sensitization in response to inhibition of CK2, we first investigated whether inhibition of 
both CK2 and PARP1 enhanced DNA strand breaks compared to inhibition of PARP 
alone. We performed comet assay to investigate the extent of DNA damage after 
treatment of AG-014799 and CX-4945 alone or the combination in MDA-MB 231 for 18 
hours.  The results showed that the cells with combination treatment had higher tail 
intensity, which is indicative of increased DNA strand breaks compared to single 
treatment and control (Figure 3.8.1.1).  Similarly, in BT549 cells, the combination 
treatment of AZD-2281 and CX-4945 had more DNA strand breaks than control and the 
single treatment (Figure 3.8.1.2). These results suggest that the inhibition of both CK2 
and PARP1 results in more DNA damage than the inhibition of either one.  
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Figure 3.8.1.1 Inhibition of CK2 and PARP Increases DNA Strand Breaks in MDA-
MB 231  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) DNA strand breaks were measured by comet assay in MDA-MB 231 cells. Cells 
were treated with AG-014699 (AG, 10 umol/L), CX-4945 (CX, 5 umol/L) or the 
combination (AG/CX) for 18 hours. 
(B) Quantification of the intensity of damaged DNA using the parameter of 
percentage of DNA in tail. *P < 0.05, Student’s t-test.  
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Figure 3.8.1.2 Inhibition of CK2 and PARP Increases DNA Strand Breaks in BT549  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) BT549 cells were treated with AZD-2281 (AZD, 10 umol/L), CX-4945 (CX, 5 
umol/L) or the combination (AZD/CX) for 18 hours and subjected to comet 
assay. 
(B) Quantification of the intensity of damaged DNA using the parameter of 
percentage of DNA in tail. *P < 0.05, Student’s t-test. 
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3.8.2 Inhibition of CK2 and PARP Enhances γ-H2AX Foci Formation 
H2AX phosphorylation (γ-H2AX) is an early step in the DNA double strand 
break (DSB) repair pathway. Therefore, it is used as a marker for measuring DNA DSBs. 
We showed that inhibition of CK2 by CX-4945 increases DNA strand breaks by comet 
assay. Next, we asked whether the combination treatment increases γ-H2AX foci 
formation compared to single treatment. Using immunofluorescence, γ-H2AX foci were 
measured in MDA-MB 231 cells by treated with AG-014699, CX-4945, and the 
combination for 48 hours (Figure 3.8.2 A). Consistent with the results in comet assay, 
inhibition of CK2 by CX-4945 enhanced the sensitivity of cells to PARPi-induced γ-
H2AX foci formation about 10 fold compared to the untreated cells (Figure 3.8.2 B). This 
result further validated that inhibition of CK2 increased PARPi-induced DNA DSBs. 
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Figure 3.8.2 Inhibition of CK2 and PARP Enhances γ-H2AX Foci Formation 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
(A) MDA-MB 231 cells were treated with AG-014699 (AG, 10 umol/L), CX-4945 
(CX, 5 umol/L) or the combination (AG/CX) for 48 hours. γ-H2AX (red) was 
detected by immunofluorescence confocal microscopy. 
(B) Quantification of γ-H2AX foci formation was shown. *P < 0.05,’s t-test.  
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3.8.3 Inhibition of CK2 and PARP Results in Cell Cycle Arrest in G2/M 
Phase  
We showed that the combination of CK2i and PARPi had higher efficacy than the 
single treatment. To further understand the underlying mechanism of the drug 
combination, we examined whether the combination treatment affect on the cell cycle. To 
address this question, we treated MDA-MB 231 cell lines with AG-014699, CX-4945 or 
the combination for 72 hours, and then the cell cycle status was detected by flow 
cytometry. The results showed that CX-4945 and AG-014699 treatment alone increased 
G2/M-phase when compared with the untreated cells by around 2% and 15%, 
respectively; while the combination significantly increased G2/M-phase around by 60% 
(Figure 3.8.3.1). The similar results were shown in BT549, in which a 40% increase in 
G2/M-phase by the combination of CX-4945 and AZD-2281 compared with the 
untreated cells was observed (Figure 3.8.3.2). This data suggest that the inhibition of both 
CK2 and PARP induces G2/M-arrest of cell cycle. This is consistent with our previous 
cell proliferation data (Figure 3.7.1.1 and 3.7.1.2), which showed that the greater growth 
retardation in the combination treatment. Moreover, we didn’t observe the significant 
increase of sub-G1 population in both cell lines, suggesting the combination doesn’t 
induce apoptosis. 
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Figure 3.8.3.1 Inhibition of CK2 and PARP Results in Cell Cycle Arrest in G2/M 
Phase in MDA-MB 231 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) MDA-MB 231 cells were treated with AG-014699 (AG, 10 umol/L), CX-4945 
(CX, 5 umol/L) or the combination (AG/CX) for 72 hours. The DNA content was 
stained with propidium iodide (PI). The cell cycle distribution was analyzed by 
flow cytometry.  
(B) Quantification of each cell cycle phase was shown. 
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 Figure 3.8.3.2 Inhibition of CK2 and PARP Results in G2/M-Phase Arrest in BT549 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) BT549 cells were treated with AZD-2281 (AZD, 10 umol/L), CX-4945 (CX, 5 
umol/L) or the combination (AZD/CX) for 72 hours. The cell cycle distribution 
was analyzed by flow cytometry. 
(B) Quantification of each cell cycle phase was shown. 
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3.9 CK2 Associates with PARP1 
3.9.1 CK2 Physically Interacts with PARP1  
As mentioned in Table 3.1, our and others mass spectrometry data showed that 
CK2 is one of PAPR1 associated kinases, and we further validated whether CK2 indeed 
interacts with PARP1 protein. CK2β subunit is critical for substrate binding, therefore we 
first overexpressed CK2β and PARP1 exogenously in 293T cells and detected the 
interaction of CK2β and PARP1 by Co-IP/western blot. We pulled down myc-CK2β and 
immunobotted HA-PARP1. Indeed, the data showed that Myc-CK2β interacts with HA-
PARP1 (Figure 3.9.1.1). Next, we performed Co-IP assay to test whether endogenous 
PARP1 interacts with endogenous CK2β in MDA-MB 231 and BT549. We pulled down 
PARP1 or CK2β and immunoblotted CK2β or PARP1, respectively. The data also 
showed that endogenous CK2β interacts with endogenous PARP1 (Figure 3.9.1.2). To 
further investigate where the interaction between CK2 and PARP1 occurs inside the cells, 
we performed proximity-ligation assay in BT549 cells. We found the majority of 
interaction happened in the cell nucleus (Figure 3.9.1.3).  
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Figure 3.9.1.1 Exogenous CK2 Interacts with PARP1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HA-PARP1 and Myc-CK2β were ectopically expressed in HEK 293FT cells, and then 
the association of PARP1 and CK2β was detected by Co-IP/Western blot. 
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Figure 3.9.1.2 Endogenous CK2 Interacts with Endogenous PARP1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The interaction of endogenous PARP1 and CK2β were determined by Co-IP/western blot. 
MDA-MB 231 and BT549 were subjected to Co-IP with anti-CK2β or anti-PARP1 
antibodies, followed by western blot with the indicate antibodies. 
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Figure 3.9.1.3 CK2 Interacts with PARP1 in the Nucleus  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proximity ligation assay (PLA) to analyze co-localization of PARP1 and CK2β (red) in 
BT549 cells. Representative images (upper panel) and quantification of PLA signals from 
50 cells (lower panel) were shown. 
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3.9.2 CK2 Phosphorylates PARP1 
Our data demonstrated that CK2 physically associated with PARP1 and also 
inhibition of CK2 sensitized TNBC to PARPi. Therefore, we hypothesized that CK2 
could phosphorylate PARP1 and regulates its function.  
Using recombinant PARP1 and CK2α proteins, we verified PAPR1 
phosphorylation by CK2α by in vitro kinase assay detecting [γ32P]-ATP (Figure 3.9.2). 
Next, we identified the phosphorylation site of PARP1 by CK2α by mass spectrometry. 
Some potential S/T phosphorylation sites on PARP1 were detected by mass spectrometry 
analysis. We are further validating the functional effect of the potential phosphorylation 
sites. 
  
	 94	
Figure 3.9.2 CK2 Phosphorylates PARP1 in vitro 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In vitro kinase assay to validate CK2-mediated phosphorylation of PARP1. Recombinant 
of His-CK2α and His-PARP1 proteins were incubated in kinase assay buffer in the 
presence of [γ32P]-ATP. Phosphorylated PARP1 and CK2α were visualized by 
autoradiography. Total PARP1 and CK2α proteins were visualized by coomassie blue 
staining. *, phosphorylated PARP1. 
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CHAPTER 4 
 
DISCUSSION and FUTURE WORKS 
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4.1 Summary of Current Findings 
 Our study revealed a new mechanism of PARPi resistance in TNBC and provided 
biomarkers to stratify patients for a rational combinational treatment with PARPi. 
Specifically, we identified c-Met, a tyrosine kinase, phosphorylates PARP1 at Y907 and 
that the phosphorylation increases PARP1 activity and resistance to PARPi. The 
combination of METi and PARPi has synergistic effect on c-Met overexpressed TNBC. 
In addition to c-Met, through database and our mass spectrometry analysis, we found 
CK2 is another potential PARP1 regulator. Briefly, CK2 is also overexpressed in TNBC, 
which is determined by TCGA analysis. The functional analysis showed that a CK2i plus 
PARPi exhibited synergy. The combination of a CK2i and PARPi attenuates DNA 
damage repair, cell cycle, and tumor growth. Similar to c-Met-PARP1 axis, CK2 interacts 
with PARP1 in the nucleus. This interaction may cause specific phosphorylation on 
PARP1 and further elevate PARP1 activity. The potential phosphorylation sites by CK2 
are still under investigation. Overall, inhibition of upstream kinases could sensitize 
PARPi-resistant cancer cells to PARPi. A phosphorylation profile in the PARP1 may 
provide marker-guided combination therapies to stratify TNBC patients (Figure 4.1).  
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Figure 4.1 The Working Model of PARPi Resistance Induced by c-Met and CK2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c-Met regulates the phosphorylation of PARP1 at Y907 and CK2 phosphorylates PARP1 
(The sites are under investigation) and enhances the PARP activity, leading to PARPi 
resistance. 
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4.2 Translational Application from Current Study 
 4.2.1 PARP1 Could be Regulated by Multiple Kinases 
PARP is currently the most promising drug target for BRCA-mutated TNBC, and 
multiple PARPi have been developed and tested in clinical trials including a single 
treatment or combinational treatment with other DNA-damage reagents and/or 
chemotherapy (39). However, not every patient with BRCA mutations responded to 
PARPi (46). Therefore, our studies provide other biomarkers to stratify patients who will 
respond to PARPi, and also develop effective combination therapies for those who will 
not respond to PARPi. We especially focused on the kinases that are inhibitors currently 
used in the clinic or in clinical trials, allowing for easier applying our biomarkers and 
combination therapies into clinical trials compared with the conventional drug 
development processes.  
 TNBC is known to be heterogenous. Previous studies have been shown that 
various kinases can phosphorylate the same substrates and resulted in signal crosstalk 
(118-120). Therefore, it is not surprised that PARP1 can be regulated by multiple kinases 
from our current study (including c-Met and CK2) in TNBC. In addition to c-Met and 
CK2, we found that EGFR could interact and phosphorylate with PARP1. Other group 
also indicated that the inhibition of both EGFR and PARP induces synthetic lethality in 
TNBC. Therefore, it is worthwhile to investigate the relationship between PARP1 and 
EGFR. Furthermore, from TCGA database analysis, we found that c-Met, EGFR and 
CK2 gene overexpression may cover at least 70% of TNBC. Thus, we expect that our 
combination treatment with PARPi and these kinase inhibitors may benefit most of 
TNBC patients. 
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4.2.2 Different Cancer Types may Show Different Response to the Same 
Combined Treatment 
Although the first PARPi (olaparib, AZD-2281) was approved by the U.S. Food 
and Drug Administration (FDA) for treatment of advanced BRCA-mutant ovarian cancer 
in December, 2014, high percentage of patients carrying BRCA mutations do not respond 
to PARPi in ovarian cancer (121).  We wondered whether our combination treatment 
could further apply to ovarian cancer. From our preliminary data, the combination of 
CK2i and PARPi showed strong synergistic effect in CK2 overexpressed ovarian cell 
lines (Figure 4.2). It has been reported that high expression of CK2 gene is correlated 
with poor survival in ovarian cancer patients (97). Therefore, it is worthwhile to 
investigate the interaction of CK2 with PARP1 in ovarian cancer. Moreover, we asked 
whether Y907 could also be a biomarker for the combination treatment of METi and 
PARPi in ovarian cancer. Surprisingly, we found that in some ovarian cell lines the 
phosphorylation of PARP1 at Y907 upon ROS stimulation can not be suppressed by 
METi, crizotinib. Thus, we suspected that other kinases might also be involved in the 
phosphorylation of PARP1 at Y907.  
  Besides TNBC and ovarian cancer, we also tested the combinational effect of c-
Met and PARP inhibitors in liver cancer and lung cancer, in which PARPi is currently 
being tested in multiple clinical trials. We demonstrated the combinational treatment of c-
Met and PARP inhibitors reduced the tumor growth in the c-Met-expressing H1993 non-
small lung cancer xenograft mice model (105). Interestingly, our preliminary data 
showed that the combination of METi and PARPi is not synergy in some liver cancer cell 
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lines, suggesting other mechanisms may compromise the inhibition of c-Met and PARP 
in liver cancer.  
 Together, the present study suggested that our strategy of targeting PARP and its 
upstream kinase is applicable to multiple cancer types. However, as described above, 
PARP1 is likely to be regulated by distinct kinases in different cancer type. Thus, the 
detail mechanisms of how PARP1 is regulated by other kinases in different cancer types 
are still waiting for further investigation. 
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Figure 4.2 The Dual-Drug Combination of CK2 and PARP Inhibitors in Multiple 
Ovarian Cancer Cell Lines Shows Synergistic Effect  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI plots for the dual drug combinations of PARPi (AZD-2281, AG-014699, ABT-888 
and BMN-673) and CX-4945 in various ovarian cancer cells.  
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4.3 Beyond BRCA Mutation and Deficiency 
PARPi are used in BRCA mutation patients through the principle of synthetic 
lethality (122, 123). Although preclinical studies indicate that PARPi shows higher 
response rates in patients carrying BRCA mutations, a high percentage of patients with 
BRCA mutations do not respond to PARPi (124). In addition, some TNBC patients with 
wild-type BRCA still respond to PARPi, therefore BRCA mutation may not be the only 
biomarker to stratify patients for PARPi treatment. The concept of “BRCAness” emerged 
as a profile of cancers that share traits with BRCA1 or BRCA2 mutated tumors (47). A 
recent paper further supported this concept that in prostate cancer, patients whose tumors 
have a set of DNA repair gene deficiency (ATM, FANCA, CHEK2, PALB2, HDAC2 
RAD51, MLH3, ERCC3, MER11, NBN, BRCA1 and BRCA2) associates with Olaparib 
response (125).  In our study, we found that the combination of METi and PARPi is 
synergy in both BRCA wild-type and BRCA mutated TNBC cell lines. For example, 
HCC1937 cells harbor BRCA mutations but resistant to PARPi. From western blot 
analysis, we found that HCC1937 cells expressed higher levels of c-Met(105). After 
knocking down c-Met, HCC1937 cells became more sensitive to PARP inhibition (105). 
We also knocked down the BRCA1 and BRCA2 expression in MDA-MB-231 cell line 
and subjected it to PARPi. Interestingly, there is no significant change for PARPi IC50 in 
BRCA1/2 knockdown MDA-MB231 cell lines (105). These results suggested that 
independent to BRCA1/2 status, c-Met overexpression could be a marker to stratify 
patients. However, we didn’t know whether c-Met or CK2 overexpression is associated 
with other DNA repair genes deficiency in these cell lines. We could further analyze 
other DNA repair genes status in our current model system. 
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Furthermore, several studies have shown that CK2 regulated DNA DSB repair 
pathway. It has been reported that CK2 could phosphorylate BRCA1 at S1572, but the 
consequences of this interaction and phosphorylation is still unclear (126). In our study, 
we showed that the inhibition of CK2 and PARP1 enhanced DNA DSBs, therefore it 
might be interesting to investigate whether the inhibition of CK2 also impairs the DNA 
DSBs repair through the suppression of BRCA1 activity in the future. 
 
4.4 Different PARP Inhibitors Combined with the Same Kinase Inhibitor may Show 
Different Combination Efficacy 
PARPi originally were designed by inhibiting the catalytic activity 
PARP1/PARP2 (127). However, recently some studies demonstrated that catalytic 
inhibition is not the only mechanism by which PARPi show cytotoxic effects (42). Some 
PARPi such as BMN-673, AZD-2281 and AG-014699 may trap PARP1 and PARP2 on 
damaged DNA (42). Trapping PARP-DNA complexes prevent DNA replication and 
transcription, leading to cell death more effectively than catalytic inhibition (128). It has 
been reported that the capacity to trap PARP varies significantly among several PARPi 
(43). Our study showed that c-Met and CK2 can phosphorylate PARP1 and enhance its 
activity. Y907 is associated with PARP1 catalytic function. However, so far whether the 
specific kinases involved in the regulation of PARP-DNA complex is not clear yet. 
Interestingly, we found that the combination efficacies of different PARPi combined with 
CK2i are not the same, suggesting catalytic inhibition may not be the only mechanism in 
our study. The different trapping ability to PARP by PARPi may be one of the 
possibilities leading to variable combinational effect. Taken together, whether c-Met, 
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CK2 or other kinase may phosphorylate PARP to affect PARP-DNA complex is an 
interesting topic for further study. Moreover, selection of the appropriate PARPi for each 
combination therapy is important for maximizing the success of clinical trials.  
 
4.5 Increased DNA Double Strand Breaks and Replication Stress by the 
Combination Treatment of CK2 and PARP in TNBC 
 Our data showed that the combination of CK2i and PARPi enhanced more DNA 
strand breaks and phosphorylation of H2AX than the single treatment or untreated control, 
suggesting increased DNA damage by the combination. CK2 is known to be involved in 
the phosphorylation of multiple DNA single strand break and double strand break repair 
machineries such as XRCC1, XRCC4 and MRN complex (100, 129). It has been reported 
that inhibition CK2 delays γ-H2AX removal and reduces clonogenic survival of 
irradiated mammalian cells (130).  Therefore, inhibition of CK2 may not only reduce 
PARP1 activity but also abrogate double strand break repair machinery, resulting in 
synthetic lethality.   
Cell-cycle arrest causes the inhibition of proliferation. The G2/M checkpoint in 
cell cycle prevents DNA-damaged cells from entering mitosis and allows them for the 
repair of DNA that is damaged in late S or G2 phases before entering to mitosis (131). In 
our study, we observed the increase of cell-cycle arrest at G2/M phase by the combined 
treatment of CK2i and PARPi. As mentioned previously, AZD-2281 and AG-014699 
have been shown to exhibit a stronger potency to trap PARP1 and PARP2 to DNA (43). 
Protein tightly bound to DNA and consequently stalling the replication fork can cause 
replicative stress, leading to accumulation of G2-phase cell subpopulation (132). The 
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increase in G2-phase that we observed in cells treated with either CX-4945 and AZD-
2281 or AG-014699 may reflect their PARP-trapping ability and induction of replicative 
stress response. However, from cell cycle analysis, the sub-G1 population is not 
significantly increased in the combination treatment for 72 hours. The data from annexin 
V and PI staining also supported it (data not shown). It suggested that the combination 
may cause strong cytostaticity but mild cytotoxicity. We may consider combining chemo-
drug or ionized radiation (IR) with our current combination to induce DNA damage more 
strongly, enhancing a cytotoxic effect in cells.  
 
4.6 Roles of Nuclear CKα and CK2β 
CK2 can form either the monomeric subunit or heterotetrameric subunit, which 
depends on different cell types and cellular function (97, 133). Our data showed that 
PARP1 co-immunoprecipitates with CK2β and is phosphorylated by CK2α. We have 
tried to detect the potential phosphorylation sites of PARP1 by CK2 using mass 
spectrometry analysis. However, so far we have not successfully identified the potential 
phosphorylation sites of PARP1 by CK2. There’s one possibility that we performed in 
vitro kinase assay by using recombinant CK2α and PARP1 only, but CK2α itself may not 
have strong binding ability to PAPR1 without CK2β, the substrate-binding unit. Since 
CK2α and CK2β can form tetramer, we suspected that PARP1 might be a substrate 
targeted by the holoenzyme. Therefore, it might be better using immunoprecipitation-
kinase assay to identify the phosphorylation sites of PARP1 by CK2 than in vitro kinase 
assay. 
Early studies have shown that cancer cells demonstrated a higher expression of 
CK2 in nuclear matrix when compared to normal cells (134, 135). Traditionally, CK2 
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was considered as a constitutively active kinase. However, studies have shown that CK2 
is activated in response to growth factor stimuli such as EGF (136, 137). In addition, it 
has been reported that CK2 can rapid translocate to the nuclear compartment upon heat 
shock and UV radiation (138). Using duolink assay, we observed the interaction of 
PARP1 and CK2β was mainly in the nucleus in basal-level, suggesting without any 
stimulation CK2 could interact with PARP1 in response to endogenous DNA damage.  
 
4.7 Roles of Nuclear c-Met 
A group of receptor tyrosine kinases (RTKs) have been found to translocate to 
nucleus such as EGFR, ErbB4 and c-Met (139-141). It has been proposed that RTKs 
translocate into nucleus from cell membrane is through a vesicle membrane-associated 
pathway. Take EGFR as an example, EGFR is carried by endocytic vesicles and 
transported from the cell surface to Golgi apparatus, the ER, the mitochondria, and the 
nucleus (142). The study has shown that nuclear localization signals (NLSs) and 
importin-β are involved in the nuclear translocation of EGFR (143). In our current study, 
we found that nuclear translocation of c-Met in response to ROS stimulation required a 
motor protein, dynein and SNARE (soluble NSF attachment protein receptor) protein 
syntaxin 6 (105). These two molecules are known to involve in cell trafficking. Thus, it 
suggested that c-Met may use the similar nuclear translocation pathway to EGFR. 
A previous report showed that the translocation of the full-length c-Met into the 
nucleus plays an important role in activating calcium signals (112). Furthermore, the 
constitutive activation of nuclear c-Met is associated with aggressiveness of MDA-
MB231 (144). In our study, c-Met translocated into the nucleus upon ROS stimulation. 
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The interaction of PARP1 and c-Met is also observed mainly in the nucleus, suggesting a 
distinct function of nuclear c-Met in DNA damage response from cell surface c-Met 
activated by a ligand.  
Since multiple RTKs translocate to the nucleus, some of them may also interact 
and phosphorylate PARP1. Indeed, our preliminary showed that EGFR interact and 
phosphorylate PARP1. EGFR is known to be overexpression in many cancer types 
including TNBC (145). Moreover, it has previously been shown that the combination of 
cetuximab (EGFR mAb) plus ABT-888 (PARPi) and that of lapatinib (EGFR/HER2 
inhibitor) plus ABT-888 induce synthetic lethality in head and neck cancer and TNBC, 
respectively (146, 147). Thus, we suspect the underlying mechanisms of EGFR signaling 
contributed to PARPi sensitivity may be similar to c-Met-PARP1 axis. 
 
4.8 Future Directions 
On the basis of our current study, c-Met and CK2 can positively regulate PARP1 
function and activity through phosphorylation in TNBC. More importantly, the 
phosphorylation of PARP1 contributes to PARPi resistance. The combination of METi 
and PARPi or CK2i and PARPi is likely a promising approach for overcoming resistance 
in TNBC. Regarding to this direction, there are still many extended questions remaining 
for further investigation. The potential future works from basic to translational aspect are 
list as below: 
(1) We have already shown that CK2 can phosphorylate PARP1. Therefore, what 
is the specific S/T site of PARP1 phosphorylated by CK2 and contribute to 
PARPi resistance? 
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(2) In addition to TNBC, does the combined inhibition of Met and PARP or CK2 
and PARP also exhibit synergistic therapeutic effects in other cancer types? 
(3) Our long-term goal is to use the phosphorylation profile in PARP1 protein as 
biomarkers to stratify patients for appropriate combination therapies. Are 
there any other potential phosphorylation sites of PARP1 contribute to PARPi 
resistance? 
(4) There are some kinases whose inhibitors are not available currently on our list. 
Do these kinases contribute to PARPi resistance as well? 
(5) What are the detail mechanisms for c-Met translocation into the nucleus and 
phosphorylation of PARP1 in response to ROS stimulation?  
(6) Does phosphorylation of PARP1 affect a PARP-DNA complex? 
(7) Currently, many chemotherapeutic drugs combined with PARPi are tested in 
clinical trials. Can our combinations enhance chemo-drug sensitivity and 
improve the therapeutic efficacy?  
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